Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11435743,plasma levels,"Nitric oxide plasma levels decreased in nearly all patients from 21.0 +/- 2.8 to 19.1 +/- 2.6 (p = 0.003) and then rose slightly to 19.5 +/- 2.5 micromol/l (p = 0.1) 3 and 6 h after CsA ingestion, respectively.",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),,21.0,816,DB00917,Dinoprostone
,11435743,plasma levels,"Nitric oxide plasma levels decreased in nearly all patients from 21.0 +/- 2.8 to 19.1 +/- 2.6 (p = 0.003) and then rose slightly to 19.5 +/- 2.5 micromol/l (p = 0.1) 3 and 6 h after CsA ingestion, respectively.",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),,19.1,817,DB00917,Dinoprostone
,11435743,plasma levels,"Nitric oxide plasma levels decreased in nearly all patients from 21.0 +/- 2.8 to 19.1 +/- 2.6 (p = 0.003) and then rose slightly to 19.5 +/- 2.5 micromol/l (p = 0.1) 3 and 6 h after CsA ingestion, respectively.",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),,19,818,DB00917,Dinoprostone
,11435743,Urinary excretion,Urinary excretion of NO2/NO3 decreased nonsignificantly from 269 +/- 38.8 to 259 +/- 27.7 and 254 +/- 41.6 micromol/min (p = 0.5 and 0.5).,Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[μM] / [min],269,819,DB00917,Dinoprostone
,11435743,Urinary excretion,Urinary excretion of NO2/NO3 decreased nonsignificantly from 269 +/- 38.8 to 259 +/- 27.7 and 254 +/- 41.6 micromol/min (p = 0.5 and 0.5).,Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[μM] / [min],259,820,DB00917,Dinoprostone
,11435743,Urinary excretion,Urinary excretion of NO2/NO3 decreased nonsignificantly from 269 +/- 38.8 to 259 +/- 27.7 and 254 +/- 41.6 micromol/min (p = 0.5 and 0.5).,Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[μM] / [min],254,821,DB00917,Dinoprostone
,11435743,excretion rate,"At the same time, urinary prostaglandin E2 and 6-keto-prostaglandin F(1 alpha) excretion rate declined significantly [from 1,187 +/- 254 to 1,186 +/- 351 and 730 +/- 148 pg/min (p = 0.27 and 0.02) and from 697 +/- 115 to 645 +/- 134 and 508 +/- 58.2 pg/min (p = 0.34 and 0.05)].",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[pg] / [min],"1,187",822,DB00917,Dinoprostone
,11435743,excretion rate,"At the same time, urinary prostaglandin E2 and 6-keto-prostaglandin F(1 alpha) excretion rate declined significantly [from 1,187 +/- 254 to 1,186 +/- 351 and 730 +/- 148 pg/min (p = 0.27 and 0.02) and from 697 +/- 115 to 645 +/- 134 and 508 +/- 58.2 pg/min (p = 0.34 and 0.05)].",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[pg] / [min],"1,186",823,DB00917,Dinoprostone
,11435743,excretion rate,"At the same time, urinary prostaglandin E2 and 6-keto-prostaglandin F(1 alpha) excretion rate declined significantly [from 1,187 +/- 254 to 1,186 +/- 351 and 730 +/- 148 pg/min (p = 0.27 and 0.02) and from 697 +/- 115 to 645 +/- 134 and 508 +/- 58.2 pg/min (p = 0.34 and 0.05)].",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[pg] / [min],730,824,DB00917,Dinoprostone
,11435743,excretion rate,"At the same time, urinary prostaglandin E2 and 6-keto-prostaglandin F(1 alpha) excretion rate declined significantly [from 1,187 +/- 254 to 1,186 +/- 351 and 730 +/- 148 pg/min (p = 0.27 and 0.02) and from 697 +/- 115 to 645 +/- 134 and 508 +/- 58.2 pg/min (p = 0.34 and 0.05)].",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[pg] / [min],697,825,DB00917,Dinoprostone
,11435743,excretion rate,"At the same time, urinary prostaglandin E2 and 6-keto-prostaglandin F(1 alpha) excretion rate declined significantly [from 1,187 +/- 254 to 1,186 +/- 351 and 730 +/- 148 pg/min (p = 0.27 and 0.02) and from 697 +/- 115 to 645 +/- 134 and 508 +/- 58.2 pg/min (p = 0.34 and 0.05)].",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[pg] / [min],645,826,DB00917,Dinoprostone
,11435743,excretion rate,"At the same time, urinary prostaglandin E2 and 6-keto-prostaglandin F(1 alpha) excretion rate declined significantly [from 1,187 +/- 254 to 1,186 +/- 351 and 730 +/- 148 pg/min (p = 0.27 and 0.02) and from 697 +/- 115 to 645 +/- 134 and 508 +/- 58.2 pg/min (p = 0.34 and 0.05)].",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[pg] / [min],508,827,DB00917,Dinoprostone
,18474366,IC(50),Artepillin C also decreased the number of neutrophils during peritonitis (IC(50): 0.9 (0.5-1.4) mg/kg).,"Anti-inflammatory effects of a bioavailable compound, Artepillin C, in Brazilian propolis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474366/),[mg] / [kg],0.9,6319,DB00917,Dinoprostone
,18474366,ID(50),"Treatment with Artepillin C decreased prostaglandin E(2) by 29+/-3% and 58+/-5% at 1 and 10 mg/kg, respectively, with a mean ID(50) of 8.5 (8.0-8.7) mg/kg).","Anti-inflammatory effects of a bioavailable compound, Artepillin C, in Brazilian propolis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474366/),[mg] / [kg],8.5,6320,DB00917,Dinoprostone
,18474366,IC(50),"Similarly, in in vitro models, Artepillin C (3, 10, or 100 microM) decreased nitric oxide production by RAW 264.7 cells with a mean IC(50) of 8.5 (7.8-9.2) microM.","Anti-inflammatory effects of a bioavailable compound, Artepillin C, in Brazilian propolis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474366/),μM,8.5,6321,DB00917,Dinoprostone
,18474366,IC(50),"In HEK 293 cells, Artepillin C reduced NF-kappaB activity with a mean IC(50) of 26 (22-30) mug/ml), suggesting anti-inflammatory activity, particularly during acute inflammation.","Anti-inflammatory effects of a bioavailable compound, Artepillin C, in Brazilian propolis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474366/),[μg] / [ml],26,6322,DB00917,Dinoprostone
,18474366,maximal peaks,"Lastly, Artepillin C was absorbed after an oral dose (10 mg/kg) with maximal peaks found at 1 h (22 microg/ml).","Anti-inflammatory effects of a bioavailable compound, Artepillin C, in Brazilian propolis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474366/),[μg] / [ml],22,6323,DB00917,Dinoprostone
,15854797,ED50,"The estimated ED50 values for inhibition of PGE2 production were 0.1 and 2.0 mg/kg at 6 and 24 h, respectively.",Pharmacodynamic behaviour of the selective cyclooxygenase-2 inhibitor lumiracoxib in the lipopolysaccharide-stimulated rat air pouch model. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15854797/),[mg] / [kg],0.1,10506,DB00917,Dinoprostone
,15854797,ED50,"The estimated ED50 values for inhibition of PGE2 production were 0.1 and 2.0 mg/kg at 6 and 24 h, respectively.",Pharmacodynamic behaviour of the selective cyclooxygenase-2 inhibitor lumiracoxib in the lipopolysaccharide-stimulated rat air pouch model. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15854797/),[mg] / [kg],2.0,10507,DB00917,Dinoprostone
,16005916,Cmax,"After administration of TA alone and TA+MB pharmacokinetic parameters of TA (mean values) were Cmax=1.635 and 1.125 microg ml(-1), AUC=6.451 and 3.967 microgh ml(-1), t1/2K10=2.618 and 2.291 h, Vdarea/F=1.390 and 1.725Lkg(-1), and ClB/F=0.386 and 0.552 L kg(-1) h(-1), respectively.",Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005916/),[μg] / [ml],1.635,15461,DB00917,Dinoprostone
,16005916,Cmax,"After administration of TA alone and TA+MB pharmacokinetic parameters of TA (mean values) were Cmax=1.635 and 1.125 microg ml(-1), AUC=6.451 and 3.967 microgh ml(-1), t1/2K10=2.618 and 2.291 h, Vdarea/F=1.390 and 1.725Lkg(-1), and ClB/F=0.386 and 0.552 L kg(-1) h(-1), respectively.",Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005916/),[μg] / [ml],1.125,15462,DB00917,Dinoprostone
,16005916,AUC,"After administration of TA alone and TA+MB pharmacokinetic parameters of TA (mean values) were Cmax=1.635 and 1.125 microg ml(-1), AUC=6.451 and 3.967 microgh ml(-1), t1/2K10=2.618 and 2.291 h, Vdarea/F=1.390 and 1.725Lkg(-1), and ClB/F=0.386 and 0.552 L kg(-1) h(-1), respectively.",Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005916/),[μgh] / [ml],6.451,15463,DB00917,Dinoprostone
,16005916,AUC,"After administration of TA alone and TA+MB pharmacokinetic parameters of TA (mean values) were Cmax=1.635 and 1.125 microg ml(-1), AUC=6.451 and 3.967 microgh ml(-1), t1/2K10=2.618 and 2.291 h, Vdarea/F=1.390 and 1.725Lkg(-1), and ClB/F=0.386 and 0.552 L kg(-1) h(-1), respectively.",Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005916/),[μgh] / [ml],3.967,15464,DB00917,Dinoprostone
,16005916,t1/2K10,"After administration of TA alone and TA+MB pharmacokinetic parameters of TA (mean values) were Cmax=1.635 and 1.125 microg ml(-1), AUC=6.451 and 3.967 microgh ml(-1), t1/2K10=2.618 and 2.291 h, Vdarea/F=1.390 and 1.725Lkg(-1), and ClB/F=0.386 and 0.552 L kg(-1) h(-1), respectively.",Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005916/),h,2.618,15465,DB00917,Dinoprostone
,16005916,t1/2K10,"After administration of TA alone and TA+MB pharmacokinetic parameters of TA (mean values) were Cmax=1.635 and 1.125 microg ml(-1), AUC=6.451 and 3.967 microgh ml(-1), t1/2K10=2.618 and 2.291 h, Vdarea/F=1.390 and 1.725Lkg(-1), and ClB/F=0.386 and 0.552 L kg(-1) h(-1), respectively.",Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005916/),h,2.291,15466,DB00917,Dinoprostone
,16005916,Vdarea/F,"After administration of TA alone and TA+MB pharmacokinetic parameters of TA (mean values) were Cmax=1.635 and 1.125 microg ml(-1), AUC=6.451 and 3.967 microgh ml(-1), t1/2K10=2.618 and 2.291 h, Vdarea/F=1.390 and 1.725Lkg(-1), and ClB/F=0.386 and 0.552 L kg(-1) h(-1), respectively.",Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005916/),1/[lkg],1.390,15467,DB00917,Dinoprostone
,16005916,Vdarea/F,"After administration of TA alone and TA+MB pharmacokinetic parameters of TA (mean values) were Cmax=1.635 and 1.125 microg ml(-1), AUC=6.451 and 3.967 microgh ml(-1), t1/2K10=2.618 and 2.291 h, Vdarea/F=1.390 and 1.725Lkg(-1), and ClB/F=0.386 and 0.552 L kg(-1) h(-1), respectively.",Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005916/),1/[lkg],1.725,15468,DB00917,Dinoprostone
,16005916,ClB/F,"After administration of TA alone and TA+MB pharmacokinetic parameters of TA (mean values) were Cmax=1.635 and 1.125 microg ml(-1), AUC=6.451 and 3.967 microgh ml(-1), t1/2K10=2.618 and 2.291 h, Vdarea/F=1.390 and 1.725Lkg(-1), and ClB/F=0.386 and 0.552 L kg(-1) h(-1), respectively.",Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005916/),[l] / [h·kg],0.386,15469,DB00917,Dinoprostone
,16005916,ClB/F,"After administration of TA alone and TA+MB pharmacokinetic parameters of TA (mean values) were Cmax=1.635 and 1.125 microg ml(-1), AUC=6.451 and 3.967 microgh ml(-1), t1/2K10=2.618 and 2.291 h, Vdarea/F=1.390 and 1.725Lkg(-1), and ClB/F=0.386 and 0.552 L kg(-1) h(-1), respectively.",Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005916/),[l] / [h·kg],0.552,15470,DB00917,Dinoprostone
,16005916,Emax,"From the pharmacokinetic and eicosanoid inhibition data for TA, pharmacodynamic parameters after dosing with TA alone for serum TxB2 and exudate PGE2 expressing efficacy (Emax=69.4 and 89.7%), potency (IC50=0.717 and 0.073 microg ml(-1)), sensitivity (N=3.413 and 1.180) and equilibration time (t1/2Ke0=0.702 and 16.52 h), respectively, were determined by PK-PD modeling using an effect compartment model.",Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005916/),%,69.4,15471,DB00917,Dinoprostone
,16005916,Emax,"From the pharmacokinetic and eicosanoid inhibition data for TA, pharmacodynamic parameters after dosing with TA alone for serum TxB2 and exudate PGE2 expressing efficacy (Emax=69.4 and 89.7%), potency (IC50=0.717 and 0.073 microg ml(-1)), sensitivity (N=3.413 and 1.180) and equilibration time (t1/2Ke0=0.702 and 16.52 h), respectively, were determined by PK-PD modeling using an effect compartment model.",Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005916/),%,89.7,15472,DB00917,Dinoprostone
,16005916,IC50,"From the pharmacokinetic and eicosanoid inhibition data for TA, pharmacodynamic parameters after dosing with TA alone for serum TxB2 and exudate PGE2 expressing efficacy (Emax=69.4 and 89.7%), potency (IC50=0.717 and 0.073 microg ml(-1)), sensitivity (N=3.413 and 1.180) and equilibration time (t1/2Ke0=0.702 and 16.52 h), respectively, were determined by PK-PD modeling using an effect compartment model.",Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005916/),[μg] / [ml],0.717,15473,DB00917,Dinoprostone
,16005916,IC50,"From the pharmacokinetic and eicosanoid inhibition data for TA, pharmacodynamic parameters after dosing with TA alone for serum TxB2 and exudate PGE2 expressing efficacy (Emax=69.4 and 89.7%), potency (IC50=0.717 and 0.073 microg ml(-1)), sensitivity (N=3.413 and 1.180) and equilibration time (t1/2Ke0=0.702 and 16.52 h), respectively, were determined by PK-PD modeling using an effect compartment model.",Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005916/),[μg] / [ml],0.073,15474,DB00917,Dinoprostone
,16005916,IC50,"From the pharmacokinetic and eicosanoid inhibition data for TA, pharmacodynamic parameters after dosing with TA alone for serum TxB2 and exudate PGE2 expressing efficacy (Emax=69.4 and 89.7%), potency (IC50=0.717 and 0.073 microg ml(-1)), sensitivity (N=3.413 and 1.180) and equilibration time (t1/2Ke0=0.702 and 16.52 h), respectively, were determined by PK-PD modeling using an effect compartment model.",Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005916/),,3,15475,DB00917,Dinoprostone
,16005916,t1/2Ke0,"From the pharmacokinetic and eicosanoid inhibition data for TA, pharmacodynamic parameters after dosing with TA alone for serum TxB2 and exudate PGE2 expressing efficacy (Emax=69.4 and 89.7%), potency (IC50=0.717 and 0.073 microg ml(-1)), sensitivity (N=3.413 and 1.180) and equilibration time (t1/2Ke0=0.702 and 16.52 h), respectively, were determined by PK-PD modeling using an effect compartment model.",Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005916/),h,0.702,15476,DB00917,Dinoprostone
,16005916,t1/2Ke0,"From the pharmacokinetic and eicosanoid inhibition data for TA, pharmacodynamic parameters after dosing with TA alone for serum TxB2 and exudate PGE2 expressing efficacy (Emax=69.4 and 89.7%), potency (IC50=0.717 and 0.073 microg ml(-1)), sensitivity (N=3.413 and 1.180) and equilibration time (t1/2Ke0=0.702 and 16.52 h), respectively, were determined by PK-PD modeling using an effect compartment model.",Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005916/),h,16.52,15477,DB00917,Dinoprostone
,16005916,IC50 ratio,In this model TA was a preferential inhibitor of COX-2 (COX-1:COX-2 IC50 ratio=12:1).,Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005916/),,12:1,15478,DB00917,Dinoprostone
,32889741,IC50,"Among them, 12r showed the most potent inhibition with an IC50 value of 5.66 ± 0.47 μM.","Design, synthesis and anti-inflammatory study of novel N-heterocyclic substituted Aloe-emodin derivatives. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32889741/),μM,5.66,16394,DB00917,Dinoprostone
up to,32889741,oral bioavailability,"Importantly, 12r showed oral bioavailability of up to 55.16% and attenuated the inflammatory symptoms in an ulcerative colitis mouse model in vivo.","Design, synthesis and anti-inflammatory study of novel N-heterocyclic substituted Aloe-emodin derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32889741/),%,55.16,16395,DB00917,Dinoprostone
,1750222,half-life,"13,14-dihydro-PGE1 degraded like PGE1 in human plasma at 37 degrees C with a half-life of several hours.",[Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1750222/),h,several,19088,DB00917,Dinoprostone
,8593252,R:S ratio,"The R:S ratio in plasma was 33:1 5 min after administration, decreasing to 1:1 at 8 h.",Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),,33:1,28012,DB00917,Dinoprostone
,8593252,R:S ratio,"The R:S ratio in plasma was 33:1 5 min after administration, decreasing to 1:1 at 8 h.",Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),,1:1,28013,DB00917,Dinoprostone
,8593252,Elimination half-life,Elimination half-life was longer for the (S) (2.19 h) than the (R)-enantiomer (1.30 h) and volume of distribution was also somewhat higher for the (S)-enantiomer.,Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),h,2.19,28014,DB00917,Dinoprostone
,8593252,Elimination half-life,Elimination half-life was longer for the (S) (2.19 h) than the (R)-enantiomer (1.30 h) and volume of distribution was also somewhat higher for the (S)-enantiomer.,Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),h,1.30,28015,DB00917,Dinoprostone
,8593252,Body clearance,Body clearance values were 0.119 l/kg/h for (S)-KTP and 0.151 l/kg/h for the (R)-antipode.,Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),[l] / [h·kg],0.119,28016,DB00917,Dinoprostone
,8593252,Body clearance,Body clearance values were 0.119 l/kg/h for (S)-KTP and 0.151 l/kg/h for the (R)-antipode.,Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),[l] / [h·kg],0.151,28017,DB00917,Dinoprostone
,8593252,EC50,"EC50 values for inhibition of serum TxB2, exudate PGE2 and beta-glu and BK-induced swelling were 0.047, 0.042, 0.101, and 0.038 microgram/ml, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),[μg] / [ml],0.047,28018,DB00917,Dinoprostone
,8593252,EC50,"EC50 values for inhibition of serum TxB2, exudate PGE2 and beta-glu and BK-induced swelling were 0.047, 0.042, 0.101, and 0.038 microgram/ml, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),[μg] / [ml],0.042,28019,DB00917,Dinoprostone
,8593252,EC50,"EC50 values for inhibition of serum TxB2, exudate PGE2 and beta-glu and BK-induced swelling were 0.047, 0.042, 0.101, and 0.038 microgram/ml, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),[μg] / [ml],0.101,28020,DB00917,Dinoprostone
,8593252,EC50,"EC50 values for inhibition of serum TxB2, exudate PGE2 and beta-glu and BK-induced swelling were 0.047, 0.042, 0.101, and 0.038 microgram/ml, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593252/),[μg] / [ml],0.038,28021,DB00917,Dinoprostone
,30802981,λz -HL,"Mean λz -HL after IV administration was 6.032 hr (range 4.735-9.244 hr) resulting from a mean Vz of 584.1 ml/kg (range, 357.1-1,092 ml/kg) and plasma clearance of 67.11 ml kg-1 hr-1 (range, 45.57-82.35 ml kg-1 hr-1 ).",Pharmacokinetics and pharmacodynamics of intravenous and transdermal flunixin meglumine in meat goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30802981/),h,6.032,35471,DB00917,Dinoprostone
,30802981,Vz,"Mean λz -HL after IV administration was 6.032 hr (range 4.735-9.244 hr) resulting from a mean Vz of 584.1 ml/kg (range, 357.1-1,092 ml/kg) and plasma clearance of 67.11 ml kg-1 hr-1 (range, 45.57-82.35 ml kg-1 hr-1 ).",Pharmacokinetics and pharmacodynamics of intravenous and transdermal flunixin meglumine in meat goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30802981/),[ml] / [kg],584.1,35472,DB00917,Dinoprostone
,30802981,plasma clearance,"Mean λz -HL after IV administration was 6.032 hr (range 4.735-9.244 hr) resulting from a mean Vz of 584.1 ml/kg (range, 357.1-1,092 ml/kg) and plasma clearance of 67.11 ml kg-1 hr-1 (range, 45.57-82.35 ml kg-1 hr-1 ).",Pharmacokinetics and pharmacodynamics of intravenous and transdermal flunixin meglumine in meat goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30802981/),[ml] / [h·kg],67.11,35473,DB00917,Dinoprostone
,30802981,Cmax,"The mean Cmax , Tmax, and λz -HL for flunixin following TD administration was 0.134 μg/ml (range, 0.050-0.188 μg/ml), 11.41 hr (range, 6.00-36.00 hr), and 43.12 hr (15.98-62.49 hr), respectively.",Pharmacokinetics and pharmacodynamics of intravenous and transdermal flunixin meglumine in meat goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30802981/),[μg] / [ml],0.134,35474,DB00917,Dinoprostone
,30802981,Tmax,"The mean Cmax , Tmax, and λz -HL for flunixin following TD administration was 0.134 μg/ml (range, 0.050-0.188 μg/ml), 11.41 hr (range, 6.00-36.00 hr), and 43.12 hr (15.98-62.49 hr), respectively.",Pharmacokinetics and pharmacodynamics of intravenous and transdermal flunixin meglumine in meat goats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30802981/),h,11.41,35475,DB00917,Dinoprostone
,30802981,λz -HL,"The mean Cmax , Tmax, and λz -HL for flunixin following TD administration was 0.134 μg/ml (range, 0.050-0.188 μg/ml), 11.41 hr (range, 6.00-36.00 hr), and 43.12 hr (15.98-62.49 hr), respectively.",Pharmacokinetics and pharmacodynamics of intravenous and transdermal flunixin meglumine in meat goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30802981/),h,43.12,35476,DB00917,Dinoprostone
,30802981,bioavailability,The mean bioavailability for TD flunixin was calculated as 24.76%.,Pharmacokinetics and pharmacodynamics of intravenous and transdermal flunixin meglumine in meat goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30802981/),%,24.76,35477,DB00917,Dinoprostone
,30802981,80% inhibitory concentration (IC80 ),"The mean 80% inhibitory concentration (IC80 ) of PGE2 by flunixin meglumine was 0.28 μg/ml (range, 0.08-0.69 μg/ml) and was only achieved with IV formulation of flunixin in this study.",Pharmacokinetics and pharmacodynamics of intravenous and transdermal flunixin meglumine in meat goats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30802981/),[μg] / [ml],0.28,35478,DB00917,Dinoprostone
,30076448,Ki,"ASP7657 exhibited high affinity for rat and human EP4 receptors, with Ki values of 6.02 nM and 2.21 nM, respectively.","Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076448/),nM,6.02,38032,DB00917,Dinoprostone
,30076448,Ki,"ASP7657 exhibited high affinity for rat and human EP4 receptors, with Ki values of 6.02 nM and 2.21 nM, respectively.","Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076448/),nM,2.21,38033,DB00917,Dinoprostone
,30076448,IC50,"In addition, ASP7657 potently inhibited the PGE2-induced cyclic adenosine monophosphate (cAMP) increase in Chinese hamster ovary (CHO) cells expressing rat EP4 receptors and human lymphoblastoid T (Jurkat) cells, with IC50 values of 0.86 nM and 0.29 nM, respectively.","Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076448/),nM,0.86,38034,DB00917,Dinoprostone
,30076448,IC50,"In addition, ASP7657 potently inhibited the PGE2-induced cyclic adenosine monophosphate (cAMP) increase in Chinese hamster ovary (CHO) cells expressing rat EP4 receptors and human lymphoblastoid T (Jurkat) cells, with IC50 values of 0.86 nM and 0.29 nM, respectively.","Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076448/),nM,0.29,38035,DB00917,Dinoprostone
,7812627,plasma osmolality,"3. In dehydrated and hyperosmolal-hydrated rabbits, plasma osmolality was 321 +/- 1 and 313 +/- 1 mOsm kg-1, respectively (P < 0.01 compared to controls, 285 +/- 1 mOsm kg-1).",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[mosm] / [kg],321,40565,DB00917,Dinoprostone
,7812627,plasma osmolality,"3. In dehydrated and hyperosmolal-hydrated rabbits, plasma osmolality was 321 +/- 1 and 313 +/- 1 mOsm kg-1, respectively (P < 0.01 compared to controls, 285 +/- 1 mOsm kg-1).",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[mosm] / [kg],313,40566,DB00917,Dinoprostone
,7812627,plasma osmolality,"3. In dehydrated and hyperosmolal-hydrated rabbits, plasma osmolality was 321 +/- 1 and 313 +/- 1 mOsm kg-1, respectively (P < 0.01 compared to controls, 285 +/- 1 mOsm kg-1).",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[mosm] / [kg],285,40567,DB00917,Dinoprostone
,7812627,systemic clearance,"4. Under both experimental conditions, lignocaine plasma concentrations were almost double (P < 0.01) those in controls, due to a lower systemic clearance, e.g. 54 +/- 3 and 59 +/- 1 vs. 96 +/- 5 ml min-1 kg-1, respectively.",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[ml] / [kg·min],54,40568,DB00917,Dinoprostone
,7812627,systemic clearance,"4. Under both experimental conditions, lignocaine plasma concentrations were almost double (P < 0.01) those in controls, due to a lower systemic clearance, e.g. 54 +/- 3 and 59 +/- 1 vs. 96 +/- 5 ml min-1 kg-1, respectively.",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[ml] / [kg·min],59,40569,DB00917,Dinoprostone
,7812627,systemic clearance,"4. Under both experimental conditions, lignocaine plasma concentrations were almost double (P < 0.01) those in controls, due to a lower systemic clearance, e.g. 54 +/- 3 and 59 +/- 1 vs. 96 +/- 5 ml min-1 kg-1, respectively.",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[ml] / [kg·min],96,40570,DB00917,Dinoprostone
,7812627,hepatic plasma flow,AVP reduced hepatic plasma flow from 38.9 +/-2.7 ml min-1 to 19.6 +/-2.5 ml min-1 (P<0.01).,Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[ml] / [min],38.9,40571,DB00917,Dinoprostone
,7812627,hepatic plasma flow,AVP reduced hepatic plasma flow from 38.9 +/-2.7 ml min-1 to 19.6 +/-2.5 ml min-1 (P<0.01).,Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[ml] / [min],19.6,40572,DB00917,Dinoprostone
,7812627,Emax,"The predicted maximal AVP-induced decrease in hepatic plasma flow was 19.6 ml min-1 kg- 1(Emax), and AVP concentration eliciting 50% of Em.. (ED50) was 28.7 pg ml-1.6",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[1·kg-·ml] / [min],19.6,40573,DB00917,Dinoprostone
,7812627,Em.. (,"The predicted maximal AVP-induced decrease in hepatic plasma flow was 19.6 ml min-1 kg- 1(Emax), and AVP concentration eliciting 50% of Em.. (ED50) was 28.7 pg ml-1.6",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[pg] / [ml],28.7,40574,DB00917,Dinoprostone
,7812627,ED50),"The predicted maximal AVP-induced decrease in hepatic plasma flow was 19.6 ml min-1 kg- 1(Emax), and AVP concentration eliciting 50% of Em.. (ED50) was 28.7 pg ml-1.6",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[pg] / [ml],28.7,40575,DB00917,Dinoprostone
,14696676,AUC,"The AUC of LPS- and PGE2-induced aqueous flare elevation was 4685 and 1386 arbitrary units, respectively.",Effects of oral administration of Gardeniae fructus extract and intravenous injection of crocetin on lipopolysaccharide- and prostaglandin E2-induced elevation of aqueous flare in pigmented rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14696676/),arbitrary·units,4685,43469,DB00917,Dinoprostone
,14696676,AUC,"The AUC of LPS- and PGE2-induced aqueous flare elevation was 4685 and 1386 arbitrary units, respectively.",Effects of oral administration of Gardeniae fructus extract and intravenous injection of crocetin on lipopolysaccharide- and prostaglandin E2-induced elevation of aqueous flare in pigmented rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14696676/),arbitrary·units,1386,43470,DB00917,Dinoprostone
,14696676,AUC,Pretreatment by oral administration of 0.15% extract of Gardeniae fructus suppressed LPS-induced aqueous flare elevation (AUC: 1411 arbitrary units).,Effects of oral administration of Gardeniae fructus extract and intravenous injection of crocetin on lipopolysaccharide- and prostaglandin E2-induced elevation of aqueous flare in pigmented rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14696676/),arbitrary·units,1411,43471,DB00917,Dinoprostone
,14696676,AUC,"Pretreatment with 3 or 30 microg/kg of crocetin did not inhibit PGE2-induced aqueous flare elevation, but 300 microg/kg of crocetin inhibited PGE2-induced aqueous flare elevation (AUC: 918 arbitrary units).",Effects of oral administration of Gardeniae fructus extract and intravenous injection of crocetin on lipopolysaccharide- and prostaglandin E2-induced elevation of aqueous flare in pigmented rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14696676/),arbitrary·units,918,43472,DB00917,Dinoprostone
,28115830,times to maximum concentration,"After a single oral dose of the ibuprofen formulations, the median times to maximum concentration were 0.42, 0.5, and 1.25 hours in ibuprofen arginine, solubilized ibuprofen capsule, and ibuprofen, respectively.",Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28115830/),h,0.42,46600,DB00917,Dinoprostone
,28115830,times to maximum concentration,"After a single oral dose of the ibuprofen formulations, the median times to maximum concentration were 0.42, 0.5, and 1.25 hours in ibuprofen arginine, solubilized ibuprofen capsule, and ibuprofen, respectively.",Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28115830/),h,0.5,46601,DB00917,Dinoprostone
,28115830,times to maximum concentration,"After a single oral dose of the ibuprofen formulations, the median times to maximum concentration were 0.42, 0.5, and 1.25 hours in ibuprofen arginine, solubilized ibuprofen capsule, and ibuprofen, respectively.",Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28115830/),h,1.25,46602,DB00917,Dinoprostone
,9131946,maximum,"After administration of R-flurbiprofen, there was a mean maximum TXB2 inhibition of 65.2 +/- 15.0% in serum but no significant changes of PGE2 levels in blister fluid were observed.",Disposition and effects of flurbiprofen enantiomers in human serum and blister fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131946/),%,65.2,49883,DB00917,Dinoprostone
,9131946,EC50,"For inhibition of TXB2 generation after administration of S-flurbiprofen, a sigmoidal log-linear concentration-response relationship was established in all subjects (EC50: 0.123 +/- 0.092 microgram ml-1).",Disposition and effects of flurbiprofen enantiomers in human serum and blister fluid. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131946/),[μg] / [ml],0.123,49884,DB00917,Dinoprostone
,22913421,area under the serum concentration-time curve (AUC0-96 h,"S(+) enantiomer means for area under the serum concentration-time curve (AUC0-96 h were 136.9 and 128.3 μg·h/mL and means for the terminal half-life (T(1/2) k10 ) were = 12.9 and 17.3 h for carprofen alone and in combination with oxytetracycline, respectively.",Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913421/),[h·μg] / [ml],136.9,52646,DB00917,Dinoprostone
,22913421,area under the serum concentration-time curve (AUC0-96 h,"S(+) enantiomer means for area under the serum concentration-time curve (AUC0-96 h were 136.9 and 128.3 μg·h/mL and means for the terminal half-life (T(1/2) k10 ) were = 12.9 and 17.3 h for carprofen alone and in combination with oxytetracycline, respectively.",Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913421/),[h·μg] / [ml],128.3,52647,DB00917,Dinoprostone
,22913421,terminal half-life (T(1/2) k10 ),"S(+) enantiomer means for area under the serum concentration-time curve (AUC0-96 h were 136.9 and 128.3 μg·h/mL and means for the terminal half-life (T(1/2) k10 ) were = 12.9 and 17.3 h for carprofen alone and in combination with oxytetracycline, respectively.",Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913421/),h,12.9,52648,DB00917,Dinoprostone
,22913421,terminal half-life (T(1/2) k10 ),"S(+) enantiomer means for area under the serum concentration-time curve (AUC0-96 h were 136.9 and 128.3 μg·h/mL and means for the terminal half-life (T(1/2) k10 ) were = 12.9 and 17.3 h for carprofen alone and in combination with oxytetracycline, respectively.",Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913421/),h,17.3,52649,DB00917,Dinoprostone
,22913421,time to achieve maximum concentrations,"Inhibition of PGE2 correlated with mean time to achieve maximum concentrations in exudate of 54 and 42 h for both carprofen treatments for R(-) and S(+) enantiomers, respectively.",Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913421/),h,54,52650,DB00917,Dinoprostone
,22913421,time to achieve maximum concentrations,"Inhibition of PGE2 correlated with mean time to achieve maximum concentrations in exudate of 54 and 42 h for both carprofen treatments for R(-) and S(+) enantiomers, respectively.",Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913421/),h,42,52651,DB00917,Dinoprostone
,3141302,Maximum plasma levels,Maximum plasma levels of 17.5 micrograms/ml were observed after 2.5 h.,Transsynovial kinetics of indoprofen in patients with rheumatoid arthritis and cyclooxygenase-inhibition in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141302/),[μg] / [ml],17.5,52950,DB00917,Dinoprostone
,3141302,Peak synovial fluid concentrations,Peak synovial fluid concentrations amounted to 8.1 micrograms/ml 4 h following the last dose.,Transsynovial kinetics of indoprofen in patients with rheumatoid arthritis and cyclooxygenase-inhibition in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141302/),[μg] / [ml],8.1,52951,DB00917,Dinoprostone
,3141302,Elimination,Elimination from synovial fluid occurred at 10.6 h compared to 9.3 h from plasma.,Transsynovial kinetics of indoprofen in patients with rheumatoid arthritis and cyclooxygenase-inhibition in vitro. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141302/),h,10,52952,DB00917,Dinoprostone
,3141302,Elimination,Elimination from synovial fluid occurred at 10.6 h compared to 9.3 h from plasma.,Transsynovial kinetics of indoprofen in patients with rheumatoid arthritis and cyclooxygenase-inhibition in vitro. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141302/),h,9.3,52953,DB00917,Dinoprostone
,28400234,oral bioavailability (%F,"Besides, selected mPGES-1 tool compounds 9 and 11l provided good in vivo pharmacokinetic profile and oral bioavailability (%F=33 and 85).","Tricyclic 4,4-dimethyl-3,4-dihydrochromeno[3,4-d]imidazole derivatives as microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors: SAR and in vivo efficacy in hyperalgesia pain model. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28400234/),,33,58607,DB00917,Dinoprostone
,28400234,oral bioavailability (%F,"Besides, selected mPGES-1 tool compounds 9 and 11l provided good in vivo pharmacokinetic profile and oral bioavailability (%F=33 and 85).","Tricyclic 4,4-dimethyl-3,4-dihydrochromeno[3,4-d]imidazole derivatives as microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors: SAR and in vivo efficacy in hyperalgesia pain model. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28400234/),,85,58608,DB00917,Dinoprostone
,12972009,half-life,In amniotic fluid the half-life was between 31 and 37 hours.,Pharmacokinetics of prostaglandins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12972009/),h,31 and 37,72670,DB00917,Dinoprostone
,8587147,elimination half-life (t1/2 beta),"S(+)- and R(-)- KTP each had a short elimination half-life (t1/2 beta) of 0.42 +/- 0.08 h and 0.42 +/- 0.09 h, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),h,0.42,73070,DB00917,Dinoprostone
,8587147,elimination half-life (t1/2 beta),"S(+)- and R(-)- KTP each had a short elimination half-life (t1/2 beta) of 0.42 +/- 0.08 h and 0.42 +/- 0.09 h, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),h,0.42,73071,DB00917,Dinoprostone
,8587147,volume of distribution (Vd),"The volume of distribution (Vd) was low, values of 0.20 +/- 0.06 L/kg and 0.22 +/- 0.06 L/kg being obtained for R(-) and S(+)KTP, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),[l] / [kg],0.20,73072,DB00917,Dinoprostone
,8587147,volume of distribution (Vd),"The volume of distribution (Vd) was low, values of 0.20 +/- 0.06 L/kg and 0.22 +/- 0.06 L/kg being obtained for R(-) and S(+)KTP, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),[l] / [kg],0.22,73073,DB00917,Dinoprostone
,8587147,elimination half-life,"Body clearance (ClB) was high, correlating with the short elimination half-life, 0.33 +/- 0.03 L/kg/h [R(-)KTP] and 0.32 +/- 0.04 L/kg/h [S(+)-KTP].",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),[l] / [h·kg],0.33,73074,DB00917,Dinoprostone
,8587147,elimination half-life,"Body clearance (ClB) was high, correlating with the short elimination half-life, 0.33 +/- 0.03 L/kg/h [R(-)KTP] and 0.32 +/- 0.04 L/kg/h [S(+)-KTP].",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),[l] / [h·kg],0.32,73075,DB00917,Dinoprostone
,8587147,EC50,"The mean EC50 values for inhibition of serum TxB2, exudate PGE2 and beta-glu and BK-induced swelling were 0.118, 0.086, 0.06 and 0.00029 microgram/mL, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),[μg] / [ml],0.118,73076,DB00917,Dinoprostone
,8587147,EC50,"The mean EC50 values for inhibition of serum TxB2, exudate PGE2 and beta-glu and BK-induced swelling were 0.118, 0.086, 0.06 and 0.00029 microgram/mL, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),[μg] / [ml],0.086,73077,DB00917,Dinoprostone
,8587147,EC50,"The mean EC50 values for inhibition of serum TxB2, exudate PGE2 and beta-glu and BK-induced swelling were 0.118, 0.086, 0.06 and 0.00029 microgram/mL, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),[μg] / [ml],0.06,73078,DB00917,Dinoprostone
,8587147,EC50,"The mean EC50 values for inhibition of serum TxB2, exudate PGE2 and beta-glu and BK-induced swelling were 0.118, 0.086, 0.06 and 0.00029 microgram/mL, respectively.",Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587147/),[μg] / [ml],0.00029,73079,DB00917,Dinoprostone
,8819190,elimination half-life (T1/2 beta),The drug had a shorter mean (SEM) elimination half-life (T1/2 beta) of 2.5 (0.95) hours and a larger volume of distribution (Vdarea) of 0.98 (0.28) litre kg-1 than other non-steroidal anti-inflammatory drugs.,Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8819190/),h,2.5,80236,DB00917,Dinoprostone
,8819190,volume of distribution (Vdarea),The drug had a shorter mean (SEM) elimination half-life (T1/2 beta) of 2.5 (0.95) hours and a larger volume of distribution (Vdarea) of 0.98 (0.28) litre kg-1 than other non-steroidal anti-inflammatory drugs.,Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8819190/),[l] / [kg],0.98,80237,DB00917,Dinoprostone
,8819190,body clearance,Its body clearance was high with a mean value of 0.30 (0.06) litre kg-1 h-1.,Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8819190/),[l] / [h·kg],0.30,80238,DB00917,Dinoprostone
,8819190,EC50,"Its mean EC50 values were lower for exudate PGE2, beta-glucuronidase and bradykinin-induced swelling inhibition (0.077 [0.018]; 0.040 [0.017] and 0.030 [0.020] microgram ml-1, respectively) than for serum TxB2 inhibition (0.137 (0.079) microgram ml-1).",Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8819190/),[μg] / [ml],0.077,80239,DB00917,Dinoprostone
,8819190,EC50,"Its mean EC50 values were lower for exudate PGE2, beta-glucuronidase and bradykinin-induced swelling inhibition (0.077 [0.018]; 0.040 [0.017] and 0.030 [0.020] microgram ml-1, respectively) than for serum TxB2 inhibition (0.137 (0.079) microgram ml-1).",Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8819190/),[μg] / [ml],0.040,80240,DB00917,Dinoprostone
,8819190,EC50,"Its mean EC50 values were lower for exudate PGE2, beta-glucuronidase and bradykinin-induced swelling inhibition (0.077 [0.018]; 0.040 [0.017] and 0.030 [0.020] microgram ml-1, respectively) than for serum TxB2 inhibition (0.137 (0.079) microgram ml-1).",Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8819190/),[μg] / [ml],0.030,80241,DB00917,Dinoprostone
,8819190,EC50,"Its mean EC50 values were lower for exudate PGE2, beta-glucuronidase and bradykinin-induced swelling inhibition (0.077 [0.018]; 0.040 [0.017] and 0.030 [0.020] microgram ml-1, respectively) than for serum TxB2 inhibition (0.137 (0.079) microgram ml-1).",Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8819190/),[μg] / [ml],0.137,80242,DB00917,Dinoprostone
,23338686,maximum concentration (Cmax,"Regarding its pharmacokinetics in mice, after a single intraperitoneal injection of PTI, its plasma levels reached the maximum concentration (Cmax = 46 μM) at 2h (Tmax) and became undetectable at 4h.","The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23338686/),μM,46,81883,DB00917,Dinoprostone
,23338686,plasma Cmax,"Indomethacin is the major metabolite of PTI, with plasma Cmax = 378 μM and Tmax = 2.5h; it became undetectable 24h postadministration.","The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23338686/),μM,378,81884,DB00917,Dinoprostone
,23338686,Tmax,"Indomethacin is the major metabolite of PTI, with plasma Cmax = 378 μM and Tmax = 2.5h; it became undetectable 24h postadministration.","The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23338686/),h,2.5,81885,DB00917,Dinoprostone
,31353535,t1/2 λz,"Mean t1/2 λz after IV administration was 4.531 hr (range 3.355 to 5.571 hr) resulting from a mean Vz of 570.6 ml/kg (range, 387.3 to 1,142 ml/kg) and plasma clearance of 87.26 ml kg-1 hr-1 (range, 55.45-179.3 ml kg-1 hr-1 ).",Pharmacokinetics and pharmacodynamics of intravenous and transdermal flunixin meglumine in alpacas. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353535/),h,4.531,94480,DB00917,Dinoprostone
,31353535,Vz,"Mean t1/2 λz after IV administration was 4.531 hr (range 3.355 to 5.571 hr) resulting from a mean Vz of 570.6 ml/kg (range, 387.3 to 1,142 ml/kg) and plasma clearance of 87.26 ml kg-1 hr-1 (range, 55.45-179.3 ml kg-1 hr-1 ).",Pharmacokinetics and pharmacodynamics of intravenous and transdermal flunixin meglumine in alpacas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353535/),[ml] / [kg],570.6,94481,DB00917,Dinoprostone
,31353535,plasma clearance,"Mean t1/2 λz after IV administration was 4.531 hr (range 3.355 to 5.571 hr) resulting from a mean Vz of 570.6 ml/kg (range, 387.3 to 1,142 ml/kg) and plasma clearance of 87.26 ml kg-1 hr-1 (range, 55.45-179.3 ml kg-1 hr-1 ).",Pharmacokinetics and pharmacodynamics of intravenous and transdermal flunixin meglumine in alpacas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353535/),[ml] / [h·kg],87.26,94482,DB00917,Dinoprostone
,31353535,Cmax,"The mean Cmax, Tmax and t1/2 λz for flunixin following TD administration were 106.4 ng/ml (range, 56.98 to 168.6 ng/ml), 13.57 hr (range, 6.000-34.00 hr) and 24.06 hr (18.63 to 39.5 hr), respectively.",Pharmacokinetics and pharmacodynamics of intravenous and transdermal flunixin meglumine in alpacas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353535/),[ng] / [ml],106.4,94483,DB00917,Dinoprostone
,31353535,Tmax,"The mean Cmax, Tmax and t1/2 λz for flunixin following TD administration were 106.4 ng/ml (range, 56.98 to 168.6 ng/ml), 13.57 hr (range, 6.000-34.00 hr) and 24.06 hr (18.63 to 39.5 hr), respectively.",Pharmacokinetics and pharmacodynamics of intravenous and transdermal flunixin meglumine in alpacas. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353535/),h,13.57,94484,DB00917,Dinoprostone
,31353535,t1/2 λz,"The mean Cmax, Tmax and t1/2 λz for flunixin following TD administration were 106.4 ng/ml (range, 56.98 to 168.6 ng/ml), 13.57 hr (range, 6.000-34.00 hr) and 24.06 hr (18.63 to 39.5 hr), respectively.",Pharmacokinetics and pharmacodynamics of intravenous and transdermal flunixin meglumine in alpacas. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353535/),h,24.06,94485,DB00917,Dinoprostone
,31353535,bioavailability,The mean bioavailability for TD flunixin was calculated as 25.05%.,Pharmacokinetics and pharmacodynamics of intravenous and transdermal flunixin meglumine in alpacas. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353535/),%,25.05,94486,DB00917,Dinoprostone
,31353535,80% inhibitory concentration (IC80 ),"The mean 80% inhibitory concentration (IC80 ) of PGE2 by flunixin meglumine was 0.23 µg/ml (range, 0.01 to 1.38 µg/ml).",Pharmacokinetics and pharmacodynamics of intravenous and transdermal flunixin meglumine in alpacas. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353535/),[μg] / [ml],0.23,94487,DB00917,Dinoprostone
,12534640,CL/F,"There was no evidence of impaired metabolism of oral diclofenac in heterozygous and homozygous carriers of the CYP2C9 alleles *2 and *3 compared with the wild type (mean CL/F (95% CI) 20.5 (11, 30) l h-1 for *1/*1, 29.9 (19, 40) l h-1 for *1/*2, 30.0 (4, 56) l h-1 for *2/*2, 22.6 (12, 33) l h-1 for *1/*3, 23.5 (11, 37) l h-1 for *3/*3 and 37.3 (-15, 89) l h-1 in *2/*3).",Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534640/),[l] / [h],20.5,96987,DB00917,Dinoprostone
,12534640,CL/F,"There was no evidence of impaired metabolism of oral diclofenac in heterozygous and homozygous carriers of the CYP2C9 alleles *2 and *3 compared with the wild type (mean CL/F (95% CI) 20.5 (11, 30) l h-1 for *1/*1, 29.9 (19, 40) l h-1 for *1/*2, 30.0 (4, 56) l h-1 for *2/*2, 22.6 (12, 33) l h-1 for *1/*3, 23.5 (11, 37) l h-1 for *3/*3 and 37.3 (-15, 89) l h-1 in *2/*3).",Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534640/),[l] / [h],29.9,96988,DB00917,Dinoprostone
,12534640,CL/F,"There was no evidence of impaired metabolism of oral diclofenac in heterozygous and homozygous carriers of the CYP2C9 alleles *2 and *3 compared with the wild type (mean CL/F (95% CI) 20.5 (11, 30) l h-1 for *1/*1, 29.9 (19, 40) l h-1 for *1/*2, 30.0 (4, 56) l h-1 for *2/*2, 22.6 (12, 33) l h-1 for *1/*3, 23.5 (11, 37) l h-1 for *3/*3 and 37.3 (-15, 89) l h-1 in *2/*3).",Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534640/),[l] / [h],30.0,96989,DB00917,Dinoprostone
,12534640,CL/F,"There was no evidence of impaired metabolism of oral diclofenac in heterozygous and homozygous carriers of the CYP2C9 alleles *2 and *3 compared with the wild type (mean CL/F (95% CI) 20.5 (11, 30) l h-1 for *1/*1, 29.9 (19, 40) l h-1 for *1/*2, 30.0 (4, 56) l h-1 for *2/*2, 22.6 (12, 33) l h-1 for *1/*3, 23.5 (11, 37) l h-1 for *3/*3 and 37.3 (-15, 89) l h-1 in *2/*3).",Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534640/),[l] / [h],22.6,96990,DB00917,Dinoprostone
,12534640,CL/F,"There was no evidence of impaired metabolism of oral diclofenac in heterozygous and homozygous carriers of the CYP2C9 alleles *2 and *3 compared with the wild type (mean CL/F (95% CI) 20.5 (11, 30) l h-1 for *1/*1, 29.9 (19, 40) l h-1 for *1/*2, 30.0 (4, 56) l h-1 for *2/*2, 22.6 (12, 33) l h-1 for *1/*3, 23.5 (11, 37) l h-1 for *3/*3 and 37.3 (-15, 89) l h-1 in *2/*3).",Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534640/),[l] / [h],23.5,96991,DB00917,Dinoprostone
,12534640,CL/F,"There was no evidence of impaired metabolism of oral diclofenac in heterozygous and homozygous carriers of the CYP2C9 alleles *2 and *3 compared with the wild type (mean CL/F (95% CI) 20.5 (11, 30) l h-1 for *1/*1, 29.9 (19, 40) l h-1 for *1/*2, 30.0 (4, 56) l h-1 for *2/*2, 22.6 (12, 33) l h-1 for *1/*3, 23.5 (11, 37) l h-1 for *3/*3 and 37.3 (-15, 89) l h-1 in *2/*3).",Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534640/),[l] / [h],37.3,96992,DB00917,Dinoprostone
,8542839,elimination half-life,"Following intravenous administration of 0.7 mg racemic carprofen/kg bwt, mean values for pharmacokinetic parameters were 18.1 h (elimination half-life); 0.25 l/kg (volume of distribution, Vd[area]); 58.9 ml/min (clearance); and 57.9 micrograms/ml.h (area under plasma concentration time curve).",Pharmacodynamics and pharmacokinetics of carprofen in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8542839/),h,18.1,101824,DB00917,Dinoprostone
,8542839,"volume of distribution, Vd[area]","Following intravenous administration of 0.7 mg racemic carprofen/kg bwt, mean values for pharmacokinetic parameters were 18.1 h (elimination half-life); 0.25 l/kg (volume of distribution, Vd[area]); 58.9 ml/min (clearance); and 57.9 micrograms/ml.h (area under plasma concentration time curve).",Pharmacodynamics and pharmacokinetics of carprofen in the horse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8542839/),[l] / [kg],0.25,101825,DB00917,Dinoprostone
,8542839,clearance,"Following intravenous administration of 0.7 mg racemic carprofen/kg bwt, mean values for pharmacokinetic parameters were 18.1 h (elimination half-life); 0.25 l/kg (volume of distribution, Vd[area]); 58.9 ml/min (clearance); and 57.9 micrograms/ml.h (area under plasma concentration time curve).",Pharmacodynamics and pharmacokinetics of carprofen in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8542839/),[ml] / [min],58.9,101826,DB00917,Dinoprostone
,8542839,area under plasma concentration time curve,"Following intravenous administration of 0.7 mg racemic carprofen/kg bwt, mean values for pharmacokinetic parameters were 18.1 h (elimination half-life); 0.25 l/kg (volume of distribution, Vd[area]); 58.9 ml/min (clearance); and 57.9 micrograms/ml.h (area under plasma concentration time curve).",Pharmacodynamics and pharmacokinetics of carprofen in the horse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8542839/),[μg] / [h·ml],57.9,101827,DB00917,Dinoprostone
exceeded,8542839,exudate:plasma concentration ratios,Mean exudate:plasma concentration ratios exceeded 1.0 at all sampling times between 2 and 48 h.,Pharmacodynamics and pharmacokinetics of carprofen in the horse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8542839/),,1.0,101828,DB00917,Dinoprostone
,15886349,cumulative excretion of radioactivity,"At 144 h after the dose, the cumulative excretion of radioactivity averaged 98.2 +/- 3.44% and 97.0 +/- 4.82% in male and female rats, respectively.","Metabolism, excretion, and pharmacokinetics of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid, an EP2 receptor-selective prostaglandin E2 agonist, in male and female Sprague-Dawley rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15886349/),%,98.2,104302,DB00917,Dinoprostone
,15886349,cumulative excretion of radioactivity,"At 144 h after the dose, the cumulative excretion of radioactivity averaged 98.2 +/- 3.44% and 97.0 +/- 4.82% in male and female rats, respectively.","Metabolism, excretion, and pharmacokinetics of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid, an EP2 receptor-selective prostaglandin E2 agonist, in male and female Sprague-Dawley rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15886349/),%,97.0,104303,DB00917,Dinoprostone
,10877012,Elimination half-life,Elimination half-life ranged from 9.9 h to 17.5 h after multiple dosing with an accumulation ratio close to 2 for all doses.,"Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877012/),h,9.9,106237,DB00917,Dinoprostone
,10877012,Elimination half-life,Elimination half-life ranged from 9.9 h to 17.5 h after multiple dosing with an accumulation ratio close to 2 for all doses.,"Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877012/),h,17.5,106238,DB00917,Dinoprostone
,10877012,accumulation ratio,Elimination half-life ranged from 9.9 h to 17.5 h after multiple dosing with an accumulation ratio close to 2 for all doses.,"Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877012/),,2,106239,DB00917,Dinoprostone
,7707490,Cmax,"Higher plasma concentrations of the (-)(R) (Cmax 18 micrograms/ml, AUC0-24 118 micrograms h/ml) than the (+)(S) (Cmax 14 micrograms/ml, AUC0-24 67 micrograms h/ml) enantiomer were achieved following administration of the racemate.",Stereospecific pharmacodynamics and pharmacokinetics of carprofen in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707490/),[μg] / [ml],18,107520,DB00917,Dinoprostone
,7707490,AUC0-24,"Higher plasma concentrations of the (-)(R) (Cmax 18 micrograms/ml, AUC0-24 118 micrograms h/ml) than the (+)(S) (Cmax 14 micrograms/ml, AUC0-24 67 micrograms h/ml) enantiomer were achieved following administration of the racemate.",Stereospecific pharmacodynamics and pharmacokinetics of carprofen in the dog. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707490/),[h·μg] / [ml],118,107521,DB00917,Dinoprostone
,7707490,Cmax,"Higher plasma concentrations of the (-)(R) (Cmax 18 micrograms/ml, AUC0-24 118 micrograms h/ml) than the (+)(S) (Cmax 14 micrograms/ml, AUC0-24 67 micrograms h/ml) enantiomer were achieved following administration of the racemate.",Stereospecific pharmacodynamics and pharmacokinetics of carprofen in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707490/),[μg] / [ml],14,107522,DB00917,Dinoprostone
,7707490,AUC0-24,"Higher plasma concentrations of the (-)(R) (Cmax 18 micrograms/ml, AUC0-24 118 micrograms h/ml) than the (+)(S) (Cmax 14 micrograms/ml, AUC0-24 67 micrograms h/ml) enantiomer were achieved following administration of the racemate.",Stereospecific pharmacodynamics and pharmacokinetics of carprofen in the dog. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707490/),[h·μg] / [ml],67,107523,DB00917,Dinoprostone
,3841222,t beta 1/2,"Rats, given CC14 (6670 mg/Kg, sc), exhibited a significant increase in SGPT (425.7 +/- 51.3 mU/ml), together with impaired pharmacokinetics of intravenous diazepam (t beta 1/2: 53.87 h; AUC: 101.05 micrograms/ml/h) when compared with saline treated animal (SGPT: 33.6 +/- 3.8 mU/ml; t beta 1/2: 2.087 h; AUC: 1.37 micrograms/ml/h).",Carbon tetrachloride-induced pharmacokinetic changes of diazepam in rats are reduced by a stable analogue of prostaglandin E2 : FCE 20700. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841222/),h,53.87,109020,DB00917,Dinoprostone
,3841222,AUC,"Rats, given CC14 (6670 mg/Kg, sc), exhibited a significant increase in SGPT (425.7 +/- 51.3 mU/ml), together with impaired pharmacokinetics of intravenous diazepam (t beta 1/2: 53.87 h; AUC: 101.05 micrograms/ml/h) when compared with saline treated animal (SGPT: 33.6 +/- 3.8 mU/ml; t beta 1/2: 2.087 h; AUC: 1.37 micrograms/ml/h).",Carbon tetrachloride-induced pharmacokinetic changes of diazepam in rats are reduced by a stable analogue of prostaglandin E2 : FCE 20700. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841222/),[μg] / [h·ml],101.05,109021,DB00917,Dinoprostone
,3841222,t beta 1/2,"Rats, given CC14 (6670 mg/Kg, sc), exhibited a significant increase in SGPT (425.7 +/- 51.3 mU/ml), together with impaired pharmacokinetics of intravenous diazepam (t beta 1/2: 53.87 h; AUC: 101.05 micrograms/ml/h) when compared with saline treated animal (SGPT: 33.6 +/- 3.8 mU/ml; t beta 1/2: 2.087 h; AUC: 1.37 micrograms/ml/h).",Carbon tetrachloride-induced pharmacokinetic changes of diazepam in rats are reduced by a stable analogue of prostaglandin E2 : FCE 20700. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841222/),h,2.087,109022,DB00917,Dinoprostone
,3841222,AUC,"Rats, given CC14 (6670 mg/Kg, sc), exhibited a significant increase in SGPT (425.7 +/- 51.3 mU/ml), together with impaired pharmacokinetics of intravenous diazepam (t beta 1/2: 53.87 h; AUC: 101.05 micrograms/ml/h) when compared with saline treated animal (SGPT: 33.6 +/- 3.8 mU/ml; t beta 1/2: 2.087 h; AUC: 1.37 micrograms/ml/h).",Carbon tetrachloride-induced pharmacokinetic changes of diazepam in rats are reduced by a stable analogue of prostaglandin E2 : FCE 20700. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841222/),[μg] / [h·ml],1.37,109023,DB00917,Dinoprostone
,3841222,t beta 1/2,"FCE 20700 (5 micrograms/ml, sc) did not change, by itself, either SGPT or diazepam pharmacokinetic parameters, but significantly antagonized the changes induced by CC14 (SGPT: 45.3 +/- 5.3 mU/ml; t beta 1/2: 0.167 h; AUC: 2.426 micrograms/ml/h).",Carbon tetrachloride-induced pharmacokinetic changes of diazepam in rats are reduced by a stable analogue of prostaglandin E2 : FCE 20700. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841222/),h,0.167,109024,DB00917,Dinoprostone
,3841222,AUC,"FCE 20700 (5 micrograms/ml, sc) did not change, by itself, either SGPT or diazepam pharmacokinetic parameters, but significantly antagonized the changes induced by CC14 (SGPT: 45.3 +/- 5.3 mU/ml; t beta 1/2: 0.167 h; AUC: 2.426 micrograms/ml/h).",Carbon tetrachloride-induced pharmacokinetic changes of diazepam in rats are reduced by a stable analogue of prostaglandin E2 : FCE 20700. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841222/),[μg] / [h·ml],2.426,109025,DB00917,Dinoprostone
,8200415,area under the plasma concentration time curve (AUC),"Tolfenamic acid displayed linear pharmacokinetics since the area under the plasma concentration time curve (AUC) values were 13.74 +/- 1.88, 29.82 +/- 6.53 and 50.52 +/- 5.73 micrograms/ml.h following administration of 2, 4 and 8 mg/kg, respectively.",Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8200415/),[μg] / [h·ml],13.74,112294,DB00917,Dinoprostone
,8200415,area under the plasma concentration time curve (AUC),"Tolfenamic acid displayed linear pharmacokinetics since the area under the plasma concentration time curve (AUC) values were 13.74 +/- 1.88, 29.82 +/- 6.53 and 50.52 +/- 5.73 micrograms/ml.h following administration of 2, 4 and 8 mg/kg, respectively.",Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8200415/),[μg] / [h·ml],29.82,112295,DB00917,Dinoprostone
,8200415,area under the plasma concentration time curve (AUC),"Tolfenamic acid displayed linear pharmacokinetics since the area under the plasma concentration time curve (AUC) values were 13.74 +/- 1.88, 29.82 +/- 6.53 and 50.52 +/- 5.73 micrograms/ml.h following administration of 2, 4 and 8 mg/kg, respectively.",Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8200415/),[μg] / [h·ml],50.52,112296,DB00917,Dinoprostone
greater,8200415,Maximal inhibition,Maximal inhibition was greater than 80% at all dose rates and 97% at the 8 mg/kg dose rate 1 h after drug administration.,Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8200415/),%,80,112297,DB00917,Dinoprostone
,8200415,Maximal inhibition,Maximal inhibition was greater than 80% at all dose rates and 97% at the 8 mg/kg dose rate 1 h after drug administration.,Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8200415/),%,97,112298,DB00917,Dinoprostone
,3572803,T1/2,Trimoprostil was absorbed rapidly and eliminated with T1/2 ranging from 25 to 37 min.,Pharmacokinetics and antisecretory activity of trimoprostil in Heidenhain-pouch dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3572803/),min,25 to 37,112759,DB00917,Dinoprostone
,3572803,plasma concentration,The predicted plasma concentration associated with a 50% inhibition of acid secretion (IC50) ranged from 0.58 to 0.79 ng/ml.,Pharmacokinetics and antisecretory activity of trimoprostil in Heidenhain-pouch dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3572803/),[ng] / [ml],0.58 to 0.79,112760,DB00917,Dinoprostone
,3183962,maximum change,Intravenous injection of prostaglandin (PG) E2 (0.01-1.0 mg/kg) induced a dose-dependent increase in the rectal temperature of urethane-anesthetized rats; the maximum change attained was 0.14 +/- 0.08 to 1.38 +/- 0.16 degrees C at 23 to 51 min after injection.,Central action of prostaglandin E2 and its methyl ester in the induction of hyperthermia after their systemic administration in urethane-anesthetized rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183962/),c·degrees,0.14,114558,DB00917,Dinoprostone
,3183962,maximum change,Intravenous injection of prostaglandin (PG) E2 (0.01-1.0 mg/kg) induced a dose-dependent increase in the rectal temperature of urethane-anesthetized rats; the maximum change attained was 0.14 +/- 0.08 to 1.38 +/- 0.16 degrees C at 23 to 51 min after injection.,Central action of prostaglandin E2 and its methyl ester in the induction of hyperthermia after their systemic administration in urethane-anesthetized rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183962/),c·degrees,1.38,114559,DB00917,Dinoprostone
,3183962,content,"Using [3H]PGE2 and radioimmunoassay, we showed PGE2 to be transported into the brain immediately (15 sec) after the i.v. injection of the PG; the PGE2 content ranged from 2.3 +/- 0.5 to 102.6 +/- 5.5 ng/g of brain when given at 0.01 to 1.0 mg/kg, which was 0.07 to 0.13% of the administered dose.",Central action of prostaglandin E2 and its methyl ester in the induction of hyperthermia after their systemic administration in urethane-anesthetized rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183962/),ng,2.3,114560,DB00917,Dinoprostone
,3183962,content,"Using [3H]PGE2 and radioimmunoassay, we showed PGE2 to be transported into the brain immediately (15 sec) after the i.v. injection of the PG; the PGE2 content ranged from 2.3 +/- 0.5 to 102.6 +/- 5.5 ng/g of brain when given at 0.01 to 1.0 mg/kg, which was 0.07 to 0.13% of the administered dose.",Central action of prostaglandin E2 and its methyl ester in the induction of hyperthermia after their systemic administration in urethane-anesthetized rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183962/),ng,102.6,114561,DB00917,Dinoprostone
,3183962,half-life,"When PGE2 or PGE2-Me administered i.v. was followed in terms of PGE2, it decreased gradually in the brain with a half-life of 9.0 to 9.5 min in both cases, and was almost undetectable (less than 0.7 ng/g of brain) at the time when rectal temperature reached a peak.",Central action of prostaglandin E2 and its methyl ester in the induction of hyperthermia after their systemic administration in urethane-anesthetized rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183962/),min,9.0 to 9.5,114562,DB00917,Dinoprostone
,23434065,terminal half-live,"In plasma, the terminal half-live of flunixin, meloxicam and gabapentin were 6.0 h (range, 3.4-11.0 h), 16.7h (range, 13.7-21.3h) and 15.3h (range, 11-32.9h), respectively.","A study to compare circulating flunixin, meloxicam and gabapentin concentrations with prostaglandin E₂ levels in calves undergoing dehorning. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23434065/),h,6.0,114728,DB00917,Dinoprostone
,23434065,terminal half-live,"In plasma, the terminal half-live of flunixin, meloxicam and gabapentin were 6.0 h (range, 3.4-11.0 h), 16.7h (range, 13.7-21.3h) and 15.3h (range, 11-32.9h), respectively.","A study to compare circulating flunixin, meloxicam and gabapentin concentrations with prostaglandin E₂ levels in calves undergoing dehorning. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23434065/),h,16.7,114729,DB00917,Dinoprostone
,23434065,terminal half-live,"In plasma, the terminal half-live of flunixin, meloxicam and gabapentin were 6.0 h (range, 3.4-11.0 h), 16.7h (range, 13.7-21.3h) and 15.3h (range, 11-32.9h), respectively.","A study to compare circulating flunixin, meloxicam and gabapentin concentrations with prostaglandin E₂ levels in calves undergoing dehorning. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23434065/),h,15.3,114730,DB00917,Dinoprostone
,25088343,%,"The %PDA closed by ibuprofen (n=24) and indomethacin (n=24) is 77.7±14.1 and 77.3±11.0, respectively.",Clinical pharmacology of ibuprofen and indomethacin in preterm infants with patent ductus arteriosus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25088343/),,77.7,115576,DB00917,Dinoprostone
,25088343,%,"The %PDA closed by ibuprofen (n=24) and indomethacin (n=24) is 77.7±14.1 and 77.3±11.0, respectively.",Clinical pharmacology of ibuprofen and indomethacin in preterm infants with patent ductus arteriosus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25088343/),,77.3,115577,DB00917,Dinoprostone
,21767277,clearance,"After intravenous, subcutaneous and oral administration (2 mg/kg), the clearance of robenacoxib from blood was rapid (0.54-0.71 L·h/kg).",Pharmacokinetic/pharmacodynamic modelling of robenacoxib in a feline tissue cage model of inflammation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21767277/),[h·l] / [kg],0.54-0.71,117417,DB00917,Dinoprostone
,21767277,mean residence time (MRT),"The mean residence time (MRT) in blood was short (0.4, 1.9 and 3.3 h after intravenous, subcutaneous and oral administration, respectively), but in exudate MRT was approximately 24 h regardless of the route of administration.",Pharmacokinetic/pharmacodynamic modelling of robenacoxib in a feline tissue cage model of inflammation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21767277/),h,0.4,117418,DB00917,Dinoprostone
,21767277,mean residence time (MRT),"The mean residence time (MRT) in blood was short (0.4, 1.9 and 3.3 h after intravenous, subcutaneous and oral administration, respectively), but in exudate MRT was approximately 24 h regardless of the route of administration.",Pharmacokinetic/pharmacodynamic modelling of robenacoxib in a feline tissue cage model of inflammation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21767277/),h,1.9,117419,DB00917,Dinoprostone
,21767277,mean residence time (MRT),"The mean residence time (MRT) in blood was short (0.4, 1.9 and 3.3 h after intravenous, subcutaneous and oral administration, respectively), but in exudate MRT was approximately 24 h regardless of the route of administration.",Pharmacokinetic/pharmacodynamic modelling of robenacoxib in a feline tissue cage model of inflammation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21767277/),h,3.3,117420,DB00917,Dinoprostone
,21767277,MRT,"The mean residence time (MRT) in blood was short (0.4, 1.9 and 3.3 h after intravenous, subcutaneous and oral administration, respectively), but in exudate MRT was approximately 24 h regardless of the route of administration.",Pharmacokinetic/pharmacodynamic modelling of robenacoxib in a feline tissue cage model of inflammation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21767277/),h,24,117421,DB00917,Dinoprostone
,21767277,potency ratio (IC(50),"The potency ratio (IC(50) COX-1: IC(50) COX-2) was 171:1, and slopes of the concentration-effect relationship were 1.36 and 1.12 for COX-1 and COX-2, respectively.",Pharmacokinetic/pharmacodynamic modelling of robenacoxib in a feline tissue cage model of inflammation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21767277/),,171:1,117422,DB00917,Dinoprostone
,1545387,half-life,Peak plasma concentrations occurred 2 to 4 hr postdosing and the half-life was 8 to 15 hr over the 1- to 250-mg/kg/day dose range.,Correlation of anti-inflammatory activity with peak tissue rather than peak plasma levels of BF389. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545387/),h,8 to 15,119292,DB00917,Dinoprostone
,3950051,maximal inhibition,The maximal inhibition of gastric acid ranged from 65% reduction after 0.75 mg to 74% after 1.5 mg to 82% after 3.0-mg doses.,Trimoprostil plasma concentration-gastric acid inhibition relationships in duodenal ulcer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950051/),%,65,119921,DB00917,Dinoprostone
,3950051,maximal inhibition,The maximal inhibition of gastric acid ranged from 65% reduction after 0.75 mg to 74% after 1.5 mg to 82% after 3.0-mg doses.,Trimoprostil plasma concentration-gastric acid inhibition relationships in duodenal ulcer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950051/),%,74,119922,DB00917,Dinoprostone
,3950051,maximal inhibition,The maximal inhibition of gastric acid ranged from 65% reduction after 0.75 mg to 74% after 1.5 mg to 82% after 3.0-mg doses.,Trimoprostil plasma concentration-gastric acid inhibition relationships in duodenal ulcer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950051/),%,82,119923,DB00917,Dinoprostone
,3950051,terminal elimination half-life,Trimoprostil was rapidly absorbed and eliminated; terminal elimination half-life ranged from 21 to 45 minutes.,Trimoprostil plasma concentration-gastric acid inhibition relationships in duodenal ulcer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950051/),min,21 to 45,119924,DB00917,Dinoprostone
,3950051,IC50,An IC50 (plasma concentration needed to elicit a 50% inhibition effect) value of 0.2 ng/mL was observed at doses of 0.75 mg to 3.0 mg.,Trimoprostil plasma concentration-gastric acid inhibition relationships in duodenal ulcer patients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950051/),[ng] / [ml],0.2,119925,DB00917,Dinoprostone
,15655513,K(i),"2. Lumiracoxib inhibited purified COX-1 and COX-2 with K(i) values of 3 and 0.06 microM, respectively.",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),μM,3,123524,DB00917,Dinoprostone
,15655513,K(i),"2. Lumiracoxib inhibited purified COX-1 and COX-2 with K(i) values of 3 and 0.06 microM, respectively.",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),μM,0.06,123525,DB00917,Dinoprostone
,15655513,IC(50),"In cellular assays, lumiracoxib had an IC(50) of 0.14 microM in COX-2-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1).",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),μM,0.14,123526,DB00917,Dinoprostone
,15655513,IC(50),"3. In a human whole blood assay, IC(50) values for lumiracoxib were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515).",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),μM,0.13,123527,DB00917,Dinoprostone
,15655513,IC(50),"3. In a human whole blood assay, IC(50) values for lumiracoxib were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515).",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),μM,67,123528,DB00917,Dinoprostone
,15655513,selectivity ratio,"3. In a human whole blood assay, IC(50) values for lumiracoxib were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515).",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),,515,123529,DB00917,Dinoprostone
,15655513,ID(50),"5. Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),[mg] / [kg],33,123530,DB00917,Dinoprostone
,15655513,ID(50),"5. Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),[mg] / [kg],0.24,123531,DB00917,Dinoprostone
,3967453,Duration of effect,Trimoprostil taken after the meal had a greater effect on gastric acid secretion than when taken before the meal: Duration of effect was 5 to 5.5 hr in group B and 2 to 2.5 hr in group A.,Trimoprostil plasma concentration--gastric acid inhibition relationships: potentiation by food. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3967453/),h,5 to 5.5,129702,DB00917,Dinoprostone
,3967453,Duration of effect,Trimoprostil taken after the meal had a greater effect on gastric acid secretion than when taken before the meal: Duration of effect was 5 to 5.5 hr in group B and 2 to 2.5 hr in group A.,Trimoprostil plasma concentration--gastric acid inhibition relationships: potentiation by food. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3967453/),h,2 to 2.5,129703,DB00917,Dinoprostone
,3967453,plasma concentration,The mean plasma concentration associated with 50% inhibition of gastric acid secretion was 1.25 ng/ml.,Trimoprostil plasma concentration--gastric acid inhibition relationships: potentiation by food. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3967453/),[ng] / [ml],1.25,129704,DB00917,Dinoprostone
,10372594,"plasma concentration ratio, R:S","The plasma concentration ratio, R:S, increased from 69:31 at 5 min to 96:4 at 3 h and plasma mean AUC values were 7524 and 1639 ng x h/mL, respectively.",A pharmacodynamic and pharmacokinetic study with vedaprofen in an equine model of acute nonimmune inflammation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372594/),,69:31,131309,DB00917,Dinoprostone
,10372594,"plasma concentration ratio, R:S","The plasma concentration ratio, R:S, increased from 69:31 at 5 min to 96:4 at 3 h and plasma mean AUC values were 7524 and 1639 ng x h/mL, respectively.",A pharmacodynamic and pharmacokinetic study with vedaprofen in an equine model of acute nonimmune inflammation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372594/),,96,131310,DB00917,Dinoprostone
,10372594,AUC,"The plasma concentration ratio, R:S, increased from 69:31 at 5 min to 96:4 at 3 h and plasma mean AUC values were 7524 and 1639 ng x h/mL, respectively.",A pharmacodynamic and pharmacokinetic study with vedaprofen in an equine model of acute nonimmune inflammation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372594/),[h·ng] / [ml],7524,131311,DB00917,Dinoprostone
,10372594,AUC,"The plasma concentration ratio, R:S, increased from 69:31 at 5 min to 96:4 at 3 h and plasma mean AUC values were 7524 and 1639 ng x h/mL, respectively.",A pharmacodynamic and pharmacokinetic study with vedaprofen in an equine model of acute nonimmune inflammation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372594/),[h·ng] / [ml],1639,131312,DB00917,Dinoprostone
,10372594,maximum concentration (Cmax),"For R(-) and S(+) vedaprofen maximum concentration (Cmax) values were 2950 and 1534 ng/mL, respectively, and corresponding AUC values were 9755 and 4400 ng x h/mL.",A pharmacodynamic and pharmacokinetic study with vedaprofen in an equine model of acute nonimmune inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372594/),[ng] / [ml],2950,131313,DB00917,Dinoprostone
,10372594,maximum concentration (Cmax),"For R(-) and S(+) vedaprofen maximum concentration (Cmax) values were 2950 and 1534 ng/mL, respectively, and corresponding AUC values were 9755 and 4400 ng x h/mL.",A pharmacodynamic and pharmacokinetic study with vedaprofen in an equine model of acute nonimmune inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372594/),[ng] / [ml],1534,131314,DB00917,Dinoprostone
,10372594,AUC,"For R(-) and S(+) vedaprofen maximum concentration (Cmax) values were 2950 and 1534 ng/mL, respectively, and corresponding AUC values were 9755 and 4400 ng x h/mL.",A pharmacodynamic and pharmacokinetic study with vedaprofen in an equine model of acute nonimmune inflammation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372594/),[h·ng] / [ml],9755,131315,DB00917,Dinoprostone
,10372594,AUC,"For R(-) and S(+) vedaprofen maximum concentration (Cmax) values were 2950 and 1534 ng/mL, respectively, and corresponding AUC values were 9755 and 4400 ng x h/mL.",A pharmacodynamic and pharmacokinetic study with vedaprofen in an equine model of acute nonimmune inflammation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372594/),[h·ng] / [ml],4400,131316,DB00917,Dinoprostone
,8536660,elimination half-life (T1/2 beta),FXN elimination half-life (T1/2 beta) in plasma was 3.37 +/- 1.09 h.,Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),h,3.37,136237,DB00917,Dinoprostone
,8536660,T1/2 beta,"However, in exudate a much longer T1/2 beta was obtained (15.99 +/- 3.80 h).",Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),h,15.99,136238,DB00917,Dinoprostone
,8536660,Apparent volume of distribution (Vdarea),Apparent volume of distribution (Vdarea) for FXN was 0.317 +/- 0.126 l/kg and body clearance (ClB) was 0.058 +/- 0.004 l/kg/h.,Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),[l] / [kg],0.317,136239,DB00917,Dinoprostone
,8536660,body clearance (ClB),Apparent volume of distribution (Vdarea) for FXN was 0.317 +/- 0.126 l/kg and body clearance (ClB) was 0.058 +/- 0.004 l/kg/h.,Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),[l] / [h·kg],0.058,136240,DB00917,Dinoprostone
,8536660,T1/2 beta,"T1/2 beta values for R(-) and S(+)KTP were, respectively, 1.09 +/- 0.19 h and 1.51 +/- 0.45 h (plasma) and 19.73 +/- 2.72 h and 22.64 +/- 4.34 h (exudate), respectively.",Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),h,1.09,136241,DB00917,Dinoprostone
,8536660,T1/2 beta,"T1/2 beta values for R(-) and S(+)KTP were, respectively, 1.09 +/- 0.19 h and 1.51 +/- 0.45 h (plasma) and 19.73 +/- 2.72 h and 22.64 +/- 4.34 h (exudate), respectively.",Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),h,1.51,136242,DB00917,Dinoprostone
,8536660,T1/2 beta,"T1/2 beta values for R(-) and S(+)KTP were, respectively, 1.09 +/- 0.19 h and 1.51 +/- 0.45 h (plasma) and 19.73 +/- 2.72 h and 22.64 +/- 4.34 h (exudate), respectively.",Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),h,19.73,136243,DB00917,Dinoprostone
,8536660,T1/2 beta,"T1/2 beta values for R(-) and S(+)KTP were, respectively, 1.09 +/- 0.19 h and 1.51 +/- 0.45 h (plasma) and 19.73 +/- 2.72 h and 22.64 +/- 4.34 h (exudate), respectively.",Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),h,22.64,136244,DB00917,Dinoprostone
,8536660,ClB,"ClB values were 0.277 +/- 0.035 l/kg/h and 0.202 +/- 0.022 l/kg/h, respectively.",Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),[l] / [h·kg],0.277,136245,DB00917,Dinoprostone
,8536660,ClB,"ClB values were 0.277 +/- 0.035 l/kg/h and 0.202 +/- 0.022 l/kg/h, respectively.",Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),[l] / [h·kg],0.202,136246,DB00917,Dinoprostone
,8536660,EC50,"FXN was a more potent inhibitor of exudate PGE2, the EC50 for FXN being lower (P < 0.01) than that for KTP (0.019 +/- 0.010 microgram/ml and 0.057 +/- 0.009 microgram/ml, respectively).",Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),[μg] / [ml],0.019,136247,DB00917,Dinoprostone
,8536660,EC50,"FXN was a more potent inhibitor of exudate PGE2, the EC50 for FXN being lower (P < 0.01) than that for KTP (0.019 +/- 0.010 microgram/ml and 0.057 +/- 0.009 microgram/ml, respectively).",Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536660/),[μg] / [ml],0.057,136248,DB00917,Dinoprostone
,18471146,plasma clearance,"The plasma clearance was low (0.061 L/kg/h), the volume of distribution was low (0.19 L/kg) and the elimination half-life was short (2.7 h).",Pharmacokinetics and pharmacodynamics of meloxicam in piglets. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471146/),[l] / [h·kg],0.061,138897,DB00917,Dinoprostone
,18471146,volume of distribution,"The plasma clearance was low (0.061 L/kg/h), the volume of distribution was low (0.19 L/kg) and the elimination half-life was short (2.7 h).",Pharmacokinetics and pharmacodynamics of meloxicam in piglets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471146/),[l] / [kg],0.19,138898,DB00917,Dinoprostone
,18471146,elimination half-life,"The plasma clearance was low (0.061 L/kg/h), the volume of distribution was low (0.19 L/kg) and the elimination half-life was short (2.7 h).",Pharmacokinetics and pharmacodynamics of meloxicam in piglets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471146/),h,2.7,138899,DB00917,Dinoprostone
,10784416,IC50,"In Ussing chamber experiments, the inhibitory action of ZAL on acetylcholine-induced ion transport in the rat colonic mucosa was equipotent for both optical isomers, with IC50 values of approximately 3--4 micromol/l.",Comparison of the antidiarrheal effects of zaldaride maleate and its optical isomers in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10784416/),[μM] / [l],3--4,139985,DB00917,Dinoprostone
,10784416,ED50,"In 16,16-dimethyl prostaglandin E2-induced diarrhea, ZAL, the S(+)-isomer and the R(-)-isomer significantly ameliorated diarrhea at doses of 30, 10 and 30 mg/kg (p.o.), respectively; the ED50 values were 25, 10 and above 30 mg/kg (p.o.), respectively.",Comparison of the antidiarrheal effects of zaldaride maleate and its optical isomers in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10784416/),[mg] / [kg],25,139986,DB00917,Dinoprostone
,10784416,ED50,"In 16,16-dimethyl prostaglandin E2-induced diarrhea, ZAL, the S(+)-isomer and the R(-)-isomer significantly ameliorated diarrhea at doses of 30, 10 and 30 mg/kg (p.o.), respectively; the ED50 values were 25, 10 and above 30 mg/kg (p.o.), respectively.",Comparison of the antidiarrheal effects of zaldaride maleate and its optical isomers in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10784416/),[mg] / [kg],10,139987,DB00917,Dinoprostone
above,10784416,ED50,"In 16,16-dimethyl prostaglandin E2-induced diarrhea, ZAL, the S(+)-isomer and the R(-)-isomer significantly ameliorated diarrhea at doses of 30, 10 and 30 mg/kg (p.o.), respectively; the ED50 values were 25, 10 and above 30 mg/kg (p.o.), respectively.",Comparison of the antidiarrheal effects of zaldaride maleate and its optical isomers in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10784416/),[mg] / [kg],30,139988,DB00917,Dinoprostone
,10784416,Cmax,"The pharmacokinetic parameters after administration of 30 mg/kg (p.o.) of each compound were as follows: ZAL (Cmax: 378 ng/ml, AUC0-12: 1650 ng-h/ml); S(+)-isomer (Cmax: 565 ng/ml, AUC0-12: 2230 ng-h/ml) and R(-)-isomer (Cmax: 271 ng/ml, AUC0-12: 613 ng-h/ml) (mean, N=4).",Comparison of the antidiarrheal effects of zaldaride maleate and its optical isomers in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10784416/),[ng] / [ml],378,139989,DB00917,Dinoprostone
,10784416,AUC0-12,"The pharmacokinetic parameters after administration of 30 mg/kg (p.o.) of each compound were as follows: ZAL (Cmax: 378 ng/ml, AUC0-12: 1650 ng-h/ml); S(+)-isomer (Cmax: 565 ng/ml, AUC0-12: 2230 ng-h/ml) and R(-)-isomer (Cmax: 271 ng/ml, AUC0-12: 613 ng-h/ml) (mean, N=4).",Comparison of the antidiarrheal effects of zaldaride maleate and its optical isomers in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10784416/),[ng-h] / [ml],1650,139990,DB00917,Dinoprostone
,10784416,Cmax,"The pharmacokinetic parameters after administration of 30 mg/kg (p.o.) of each compound were as follows: ZAL (Cmax: 378 ng/ml, AUC0-12: 1650 ng-h/ml); S(+)-isomer (Cmax: 565 ng/ml, AUC0-12: 2230 ng-h/ml) and R(-)-isomer (Cmax: 271 ng/ml, AUC0-12: 613 ng-h/ml) (mean, N=4).",Comparison of the antidiarrheal effects of zaldaride maleate and its optical isomers in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10784416/),[ng] / [ml],565,139991,DB00917,Dinoprostone
,10784416,AUC0-12,"The pharmacokinetic parameters after administration of 30 mg/kg (p.o.) of each compound were as follows: ZAL (Cmax: 378 ng/ml, AUC0-12: 1650 ng-h/ml); S(+)-isomer (Cmax: 565 ng/ml, AUC0-12: 2230 ng-h/ml) and R(-)-isomer (Cmax: 271 ng/ml, AUC0-12: 613 ng-h/ml) (mean, N=4).",Comparison of the antidiarrheal effects of zaldaride maleate and its optical isomers in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10784416/),[ng-h] / [ml],2230,139992,DB00917,Dinoprostone
,10784416,Cmax,"The pharmacokinetic parameters after administration of 30 mg/kg (p.o.) of each compound were as follows: ZAL (Cmax: 378 ng/ml, AUC0-12: 1650 ng-h/ml); S(+)-isomer (Cmax: 565 ng/ml, AUC0-12: 2230 ng-h/ml) and R(-)-isomer (Cmax: 271 ng/ml, AUC0-12: 613 ng-h/ml) (mean, N=4).",Comparison of the antidiarrheal effects of zaldaride maleate and its optical isomers in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10784416/),[ng] / [ml],271,139993,DB00917,Dinoprostone
,10784416,AUC0-12,"The pharmacokinetic parameters after administration of 30 mg/kg (p.o.) of each compound were as follows: ZAL (Cmax: 378 ng/ml, AUC0-12: 1650 ng-h/ml); S(+)-isomer (Cmax: 565 ng/ml, AUC0-12: 2230 ng-h/ml) and R(-)-isomer (Cmax: 271 ng/ml, AUC0-12: 613 ng-h/ml) (mean, N=4).",Comparison of the antidiarrheal effects of zaldaride maleate and its optical isomers in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10784416/),[ng-h] / [ml],613,139994,DB00917,Dinoprostone
,12213119,clearance,"PBZ pharmacokinetics after i.v. dosage was characterized by slow clearance (1.29 mL/kg/h), long-terminal half-life (53.4 h), low distribution volume (0.09 L/kg) and low concentrations in plasma of the metabolite oxyphenbutazone (OPBZ), confirming previously published data for adult cattle.",Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),[ml] / [h·kg],1.29,140382,DB00917,Dinoprostone
,12213119,-terminal half-life,"PBZ pharmacokinetics after i.v. dosage was characterized by slow clearance (1.29 mL/kg/h), long-terminal half-life (53.4 h), low distribution volume (0.09 L/kg) and low concentrations in plasma of the metabolite oxyphenbutazone (OPBZ), confirming previously published data for adult cattle.",Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),h,53.4,140383,DB00917,Dinoprostone
,12213119,distribution volume,"PBZ pharmacokinetics after i.v. dosage was characterized by slow clearance (1.29 mL/kg/h), long-terminal half-life (53.4 h), low distribution volume (0.09 L/kg) and low concentrations in plasma of the metabolite oxyphenbutazone (OPBZ), confirming previously published data for adult cattle.",Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),[l] / [kg],0.09,140384,DB00917,Dinoprostone
,12213119,bioavailability (F),After oral dosage bioavailability (F) was 66%.,Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),%,66,140385,DB00917,Dinoprostone
,12213119,area under curve,"Passage into exudate was slow and limited, and penetration into transudate was even slower and more limited; area under curve values for plasma, exudate and transudate after i.v. dosage were 3604, 1117 and 766 microg h/mL and corresponding values after oral dosage were 2435, 647 and 486 microg h/mL.",Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),[h·μg] / [ml],3604,140386,DB00917,Dinoprostone
,12213119,area under curve,"Passage into exudate was slow and limited, and penetration into transudate was even slower and more limited; area under curve values for plasma, exudate and transudate after i.v. dosage were 3604, 1117 and 766 microg h/mL and corresponding values after oral dosage were 2435, 647 and 486 microg h/mL.",Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),[h·μg] / [ml],1117,140387,DB00917,Dinoprostone
,12213119,area under curve,"Passage into exudate was slow and limited, and penetration into transudate was even slower and more limited; area under curve values for plasma, exudate and transudate after i.v. dosage were 3604, 1117 and 766 microg h/mL and corresponding values after oral dosage were 2435, 647 and 486 microg h/mL.",Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),[h·μg] / [ml],766,140388,DB00917,Dinoprostone
,12213119,area under curve,"Passage into exudate was slow and limited, and penetration into transudate was even slower and more limited; area under curve values for plasma, exudate and transudate after i.v. dosage were 3604, 1117 and 766 microg h/mL and corresponding values after oral dosage were 2435, 647 and 486 microg h/mL.",Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),[h·μg] / [ml],2435,140389,DB00917,Dinoprostone
,12213119,area under curve,"Passage into exudate was slow and limited, and penetration into transudate was even slower and more limited; area under curve values for plasma, exudate and transudate after i.v. dosage were 3604, 1117 and 766 microg h/mL and corresponding values after oral dosage were 2435, 647 and 486 microg h/mL.",Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),[h·μg] / [ml],647,140390,DB00917,Dinoprostone
,12213119,area under curve,"Passage into exudate was slow and limited, and penetration into transudate was even slower and more limited; area under curve values for plasma, exudate and transudate after i.v. dosage were 3604, 1117 and 766 microg h/mL and corresponding values after oral dosage were 2435, 647 and 486 microg h/mL.",Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),[h·μg] / [ml],486,140391,DB00917,Dinoprostone
,8092213,metabolic clearance rate,The angiotensin II metabolic clearance rate and half-life were similar in nonpregnant and pregnant women: metabolic clearance rate = 85 +/- 10 versus 68 +/- 3 ml/min.,Angiotensin II metabolic clearance rate and pressor responses in nonpregnant and pregnant women. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092213/),[ml] / [min],85,146935,DB00917,Dinoprostone
,8092213,metabolic clearance rate,The angiotensin II metabolic clearance rate and half-life were similar in nonpregnant and pregnant women: metabolic clearance rate = 85 +/- 10 versus 68 +/- 3 ml/min.,Angiotensin II metabolic clearance rate and pressor responses in nonpregnant and pregnant women. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092213/),[ml] / [min],68,146936,DB00917,Dinoprostone
,8092213,half-life,"kg, respectively (p = 0.130), and half-life = 48 and 49 seconds, respectively.",Angiotensin II metabolic clearance rate and pressor responses in nonpregnant and pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092213/),seconds,48,146937,DB00917,Dinoprostone
,8092213,half-life,"kg, respectively (p = 0.130), and half-life = 48 and 49 seconds, respectively.",Angiotensin II metabolic clearance rate and pressor responses in nonpregnant and pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092213/),seconds,49,146938,DB00917,Dinoprostone
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,128.8,153272,DB00917,Dinoprostone
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,48.5,153273,DB00917,Dinoprostone
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,29.2,153274,DB00917,Dinoprostone
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,17.,153275,DB00917,Dinoprostone
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,7,153276,DB00917,Dinoprostone
,8835565,concentrations required for 50% inhibition (EC50),Data from the single dose study revealed that the mean (+/- SD) of the concentrations required for 50% inhibition (EC50) of platelet derived TXB2 by total naproxen was 7.7 +/- 4.4 micrograms/ml (n = 5) and for unbound drug 25.4 +/- 22.0 ng/ml (n = 5).,Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835565/),[μg] / [ml],7.7,154890,DB00917,Dinoprostone
,8835565,unbound drug,Data from the single dose study revealed that the mean (+/- SD) of the concentrations required for 50% inhibition (EC50) of platelet derived TXB2 by total naproxen was 7.7 +/- 4.4 micrograms/ml (n = 5) and for unbound drug 25.4 +/- 22.0 ng/ml (n = 5).,Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835565/),[ng] / [ml],25.4,154891,DB00917,Dinoprostone
,12485349,plasma,"R(-)-carprofen was the predominant enantiomer in all three fluids, as indicated by plasma area under the curve (AUC) values for R(-) and S(+)-carprofen of 117.4 and 22.6 microg h/mL (low dose carprofen) and 557.5 and 138.1 microg h/mL (high dose carprofen) respectively.",Pharmacodynamics and enantioselective pharmacokinetics of racemic carprofen in the horse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485349/),[h·μg] / [ml],117.4,165587,DB00917,Dinoprostone
,12485349,plasma,"R(-)-carprofen was the predominant enantiomer in all three fluids, as indicated by plasma area under the curve (AUC) values for R(-) and S(+)-carprofen of 117.4 and 22.6 microg h/mL (low dose carprofen) and 557.5 and 138.1 microg h/mL (high dose carprofen) respectively.",Pharmacodynamics and enantioselective pharmacokinetics of racemic carprofen in the horse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485349/),[h·μg] / [ml],557.5,165588,DB00917,Dinoprostone
,12485349,area under the curve (AUC),"R(-)-carprofen was the predominant enantiomer in all three fluids, as indicated by plasma area under the curve (AUC) values for R(-) and S(+)-carprofen of 117.4 and 22.6 microg h/mL (low dose carprofen) and 557.5 and 138.1 microg h/mL (high dose carprofen) respectively.",Pharmacodynamics and enantioselective pharmacokinetics of racemic carprofen in the horse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485349/),[h·μg] / [ml],117.4,165589,DB00917,Dinoprostone
,12485349,area under the curve (AUC),"R(-)-carprofen was the predominant enantiomer in all three fluids, as indicated by plasma area under the curve (AUC) values for R(-) and S(+)-carprofen of 117.4 and 22.6 microg h/mL (low dose carprofen) and 557.5 and 138.1 microg h/mL (high dose carprofen) respectively.",Pharmacodynamics and enantioselective pharmacokinetics of racemic carprofen in the horse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485349/),[h·μg] / [ml],22.6,165590,DB00917,Dinoprostone
,12485349,area under the curve (AUC),"R(-)-carprofen was the predominant enantiomer in all three fluids, as indicated by plasma area under the curve (AUC) values for R(-) and S(+)-carprofen of 117.4 and 22.6 microg h/mL (low dose carprofen) and 557.5 and 138.1 microg h/mL (high dose carprofen) respectively.",Pharmacodynamics and enantioselective pharmacokinetics of racemic carprofen in the horse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485349/),[h·μg] / [ml],557.5,165591,DB00917,Dinoprostone
,12485349,area under the curve (AUC),"R(-)-carprofen was the predominant enantiomer in all three fluids, as indicated by plasma area under the curve (AUC) values for R(-) and S(+)-carprofen of 117.4 and 22.6 microg h/mL (low dose carprofen) and 557.5 and 138.1 microg h/mL (high dose carprofen) respectively.",Pharmacodynamics and enantioselective pharmacokinetics of racemic carprofen in the horse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485349/),[h·μg] / [ml],138.1,165592,DB00917,Dinoprostone
,19679500,IC(50),"IC(50) values for PGE(2) inhibition showed a shift from 2840+/-510 to 4000+/-677ng/ml(mean+/-SD), whilst IC(50) values for TXB(2) inhibition increased from 1180+/-323 to 3360+/-453ng/ml in healthy and FCA-inoculated animals, respectively.",Impact of chronic inflammation on the pharmacokinetic-pharmacodynamic relationship of naproxen. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679500/),[ng] / [ml],2840,181391,DB00917,Dinoprostone
,19679500,IC(50),"IC(50) values for PGE(2) inhibition showed a shift from 2840+/-510 to 4000+/-677ng/ml(mean+/-SD), whilst IC(50) values for TXB(2) inhibition increased from 1180+/-323 to 3360+/-453ng/ml in healthy and FCA-inoculated animals, respectively.",Impact of chronic inflammation on the pharmacokinetic-pharmacodynamic relationship of naproxen. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679500/),[ng] / [ml],4000,181392,DB00917,Dinoprostone
,19679500,IC(50),"IC(50) values for PGE(2) inhibition showed a shift from 2840+/-510 to 4000+/-677ng/ml(mean+/-SD), whilst IC(50) values for TXB(2) inhibition increased from 1180+/-323 to 3360+/-453ng/ml in healthy and FCA-inoculated animals, respectively.",Impact of chronic inflammation on the pharmacokinetic-pharmacodynamic relationship of naproxen. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679500/),[ng] / [ml],1180,181393,DB00917,Dinoprostone
,19679500,IC(50),"IC(50) values for PGE(2) inhibition showed a shift from 2840+/-510 to 4000+/-677ng/ml(mean+/-SD), whilst IC(50) values for TXB(2) inhibition increased from 1180+/-323 to 3360+/-453ng/ml in healthy and FCA-inoculated animals, respectively.",Impact of chronic inflammation on the pharmacokinetic-pharmacodynamic relationship of naproxen. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679500/),[ng] / [ml],3360,181394,DB00917,Dinoprostone
,6948952,half-lives,"the metabolite disappeared from the circulation rapidly with half-lives of 9.9 +/- 0.2, 9.2 +/- 0.3 and 7.8 +/- 0.8 min (mean +/- S.E.M., n = 4) for the respective doses noted above.",A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6948952/),min,9.9,182394,DB00917,Dinoprostone
,6948952,half-lives,"the metabolite disappeared from the circulation rapidly with half-lives of 9.9 +/- 0.2, 9.2 +/- 0.3 and 7.8 +/- 0.8 min (mean +/- S.E.M., n = 4) for the respective doses noted above.",A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6948952/),min,9.2,182395,DB00917,Dinoprostone
,6948952,half-lives,"the metabolite disappeared from the circulation rapidly with half-lives of 9.9 +/- 0.2, 9.2 +/- 0.3 and 7.8 +/- 0.8 min (mean +/- S.E.M., n = 4) for the respective doses noted above.",A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6948952/),min,7.8,182396,DB00917,Dinoprostone
,6948952,Basal concentrations,"Basal concentrations of 48 +/- 31 pg/ml (mean +/- S.D., n = 15) in human plasma concur with concentrations measured by gas chromatography/mass spectrometry.",A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6948952/),[pg] / [ml],48,182397,DB00917,Dinoprostone
,25378135,elimination half-life,"Similar to other reports, firocoxib exhibited a long elimination half-life (31.07 ± 10.64 h), a large volume of distribution (1.81 ± 0.59L/kg), and a slow clearance (42.61 ± 11.28 mL/h/kg).",Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378135/),h,31.07,192952,DB00917,Dinoprostone
,25378135,volume of distribution,"Similar to other reports, firocoxib exhibited a long elimination half-life (31.07 ± 10.64 h), a large volume of distribution (1.81 ± 0.59L/kg), and a slow clearance (42.61 ± 11.28 mL/h/kg).",Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378135/),[l] / [kg],1.81,192953,DB00917,Dinoprostone
,25378135,clearance,"Similar to other reports, firocoxib exhibited a long elimination half-life (31.07 ± 10.64 h), a large volume of distribution (1.81 ± 0.59L/kg), and a slow clearance (42.61 ± 11.28 mL/h/kg).",Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378135/),[ml] / [h·kg],42.61,192954,DB00917,Dinoprostone
,25378135,Bioavailability,"Bioavailability was 112% and 88% for the paste and tablet, respectively.",Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378135/),%,112,192955,DB00917,Dinoprostone
,25378135,Bioavailability,"Bioavailability was 112% and 88% for the paste and tablet, respectively.",Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378135/),%,88,192956,DB00917,Dinoprostone
,25378135,Maximum inhibition,"Maximum inhibition of PGE2 was 83.76% for the I.V. formulation, 52.95% for the oral paste formulation, and 46.22% for the oral tablet formulation.",Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378135/),%,83.76,192957,DB00917,Dinoprostone
,25378135,Maximum inhibition,"Maximum inhibition of PGE2 was 83.76% for the I.V. formulation, 52.95% for the oral paste formulation, and 46.22% for the oral tablet formulation.",Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378135/),%,52.95,192958,DB00917,Dinoprostone
,25378135,Maximum inhibition,"Maximum inhibition of PGE2 was 83.76% for the I.V. formulation, 52.95% for the oral paste formulation, and 46.22% for the oral tablet formulation.",Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378135/),%,46.22,192959,DB00917,Dinoprostone
,25378135,IC50,Pharmacodynamic modeling suggests an IC50 of approximately 27 ng/mL and an IC80 of 108 ng/ mL for COX2 inhibition.,Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378135/),[ng] / [ml],27,192960,DB00917,Dinoprostone
,25378135,IC80,Pharmacodynamic modeling suggests an IC50 of approximately 27 ng/mL and an IC80 of 108 ng/ mL for COX2 inhibition.,Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378135/),[ng] / [ml],108,192961,DB00917,Dinoprostone
,19841157,AUC(0-24),"Systemic exposure was greater with oral diclofenac (AUC(0-24), 3890 +/- 1710 ng x h/mL) than with topical treatments A (AUC(0-24), 233 +/- 128 ng x h/mL) and B (AUC(0-24), 807 +/- 478 ng x h/mL).",Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841157/),[h·ng] / [ml],3890,195143,DB00917,Dinoprostone
,19841157,AUC(0-24),"Systemic exposure was greater with oral diclofenac (AUC(0-24), 3890 +/- 1710 ng x h/mL) than with topical treatments A (AUC(0-24), 233 +/- 128 ng x h/mL) and B (AUC(0-24), 807 +/- 478 ng x h/mL).",Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841157/),[h·ng] / [ml],233,195144,DB00917,Dinoprostone
,19841157,AUC(0-24),"Systemic exposure was greater with oral diclofenac (AUC(0-24), 3890 +/- 1710 ng x h/mL) than with topical treatments A (AUC(0-24), 233 +/- 128 ng x h/mL) and B (AUC(0-24), 807 +/- 478 ng x h/mL).",Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841157/),[h·ng] / [ml],807,195145,DB00917,Dinoprostone
,20840388,T(max),"In an in vivo pharmacokinetic ex vivo pharmacodynamic study, after both p.o. (1-2 mg/kg) and subcutaneous (2 mg/kg) dosing, robenacoxib achieved peak blood concentrations rapidly (T(max) = 1 h for both administration routes) and was cleared from blood relatively rapidly (mean residence time was 1.70 h after p.o. and 1.79 h after subcutaneous dosing).",In vitro and ex vivo inhibition of COX isoforms by robenacoxib in the cat: a comparative study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840388/),h,1,196332,DB00917,Dinoprostone
,20840388,mean residence time,"In an in vivo pharmacokinetic ex vivo pharmacodynamic study, after both p.o. (1-2 mg/kg) and subcutaneous (2 mg/kg) dosing, robenacoxib achieved peak blood concentrations rapidly (T(max) = 1 h for both administration routes) and was cleared from blood relatively rapidly (mean residence time was 1.70 h after p.o. and 1.79 h after subcutaneous dosing).",In vitro and ex vivo inhibition of COX isoforms by robenacoxib in the cat: a comparative study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840388/),h,1.70,196333,DB00917,Dinoprostone
,20840388,mean residence time,"In an in vivo pharmacokinetic ex vivo pharmacodynamic study, after both p.o. (1-2 mg/kg) and subcutaneous (2 mg/kg) dosing, robenacoxib achieved peak blood concentrations rapidly (T(max) = 1 h for both administration routes) and was cleared from blood relatively rapidly (mean residence time was 1.70 h after p.o. and 1.79 h after subcutaneous dosing).",In vitro and ex vivo inhibition of COX isoforms by robenacoxib in the cat: a comparative study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840388/),h,1.79,196334,DB00917,Dinoprostone
,25075617,maximum plasma concentration,"Following cimicoxib administration, the mean maximum plasma concentration was 0.16 (SD 0.01) µg/mL and 0.14 (SD 0.03) µg/mL in fasted and fed groups, respectively.",Evaluation of pharmacokinetic and pharmacodynamic properties of cimicoxib in fasted and fed horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25075617/),[μg] / [ml],0.16,198009,DB00917,Dinoprostone
,25075617,maximum plasma concentration,"Following cimicoxib administration, the mean maximum plasma concentration was 0.16 (SD 0.01) µg/mL and 0.14 (SD 0.03) µg/mL in fasted and fed groups, respectively.",Evaluation of pharmacokinetic and pharmacodynamic properties of cimicoxib in fasted and fed horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25075617/),[μg] / [ml],0.14,198010,DB00917,Dinoprostone
,25075617,time taken to reach maximum plasma concentration,"The mean time taken to reach maximum plasma concentration was longer in the fed group (5.91 (SD 3.23) hours) compared with the fasted group (3.25 (SD 1.17) hours), but this difference was not significant (p=0.12).",Evaluation of pharmacokinetic and pharmacodynamic properties of cimicoxib in fasted and fed horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25075617/),h,5.91,198011,DB00917,Dinoprostone
,25075617,time taken to reach maximum plasma concentration,"The mean time taken to reach maximum plasma concentration was longer in the fed group (5.91 (SD 3.23) hours) compared with the fasted group (3.25 (SD 1.17) hours), but this difference was not significant (p=0.12).",Evaluation of pharmacokinetic and pharmacodynamic properties of cimicoxib in fasted and fed horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25075617/),h,3.25,198012,DB00917,Dinoprostone
,25075617,maximal inhibition,"The mean maximal inhibition of TXB2 was 62.4 (SD 13.8)% and 54.6 (SD 15.4)%, and of PGE2 was 72.1 (SD 43.3)% and 68.5 (SD 24.4)%, in fasted and fed horses, respectively.",Evaluation of pharmacokinetic and pharmacodynamic properties of cimicoxib in fasted and fed horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25075617/),%,62.4,198013,DB00917,Dinoprostone
,25075617,maximal inhibition,"The mean maximal inhibition of TXB2 was 62.4 (SD 13.8)% and 54.6 (SD 15.4)%, and of PGE2 was 72.1 (SD 43.3)% and 68.5 (SD 24.4)%, in fasted and fed horses, respectively.",Evaluation of pharmacokinetic and pharmacodynamic properties of cimicoxib in fasted and fed horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25075617/),%,54.6,198014,DB00917,Dinoprostone
,25075617,maximal inhibition,"The mean maximal inhibition of TXB2 was 62.4 (SD 13.8)% and 54.6 (SD 15.4)%, and of PGE2 was 72.1 (SD 43.3)% and 68.5 (SD 24.4)%, in fasted and fed horses, respectively.",Evaluation of pharmacokinetic and pharmacodynamic properties of cimicoxib in fasted and fed horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25075617/),%,72.1,198015,DB00917,Dinoprostone
,25075617,maximal inhibition,"The mean maximal inhibition of TXB2 was 62.4 (SD 13.8)% and 54.6 (SD 15.4)%, and of PGE2 was 72.1 (SD 43.3)% and 68.5 (SD 24.4)%, in fasted and fed horses, respectively.",Evaluation of pharmacokinetic and pharmacodynamic properties of cimicoxib in fasted and fed horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25075617/),%,68.5,198016,DB00917,Dinoprostone
,11447235,t(1/2),PGE(2)-G was rapidly hydrolyzed in rat plasma to generate PGE(2) (t(1/2) = 14 s) but was only slowly metabolized in human plasma (t(1/2) > 10 min).,Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11447235/),s,14,198936,DB00917,Dinoprostone
>,11447235,t(1/2),PGE(2)-G was rapidly hydrolyzed in rat plasma to generate PGE(2) (t(1/2) = 14 s) but was only slowly metabolized in human plasma (t(1/2) > 10 min).,Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11447235/),min,10,198937,DB00917,Dinoprostone
,11447235,t(1/2),An intermediate extent of metabolism of PGE(2)-G was observed in human whole blood (t(1/2) approximately 7 min).,Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11447235/),min,7,198938,DB00917,Dinoprostone
over,11447235,half-life,"However, PGE(2)-EA was detectable up to 2 h following an identical dose, displaying a large apparent volume of distribution and a half-life of over 6 min.",Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11447235/),min,6,198939,DB00917,Dinoprostone
,6725620,half-lives of elimination,The harmonic mean half-lives of elimination were similar (P greater than 0.05) across all doses and ranged from 27 to 55 minutes.,Influence of food on the bioavailability of trimoprostil: an overview. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6725620/),min,27 to 55,201482,DB00917,Dinoprostone
,12152005,clearances,"The pharmacokinetics of racemic and of S-ibuprofen depended on the CYP2C9 isoleucine359leucine amino acid polymorphism: population mean S-ibuprofen clearances were 3.25 L/h (95% confidence interval [CI], 2.84 to 3.73), 2.38 L/h (95% CI, 2.09 to 2.73), and 1.52 L/h (95% CI, 1.33 to 1.74) in carriers of the CYP2C9 genotypes *1/*1, *1/*3, and *3/*3, respectively.",Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12152005/),[l] / [h],3.25,202163,DB00917,Dinoprostone
,12152005,clearances,"The pharmacokinetics of racemic and of S-ibuprofen depended on the CYP2C9 isoleucine359leucine amino acid polymorphism: population mean S-ibuprofen clearances were 3.25 L/h (95% confidence interval [CI], 2.84 to 3.73), 2.38 L/h (95% CI, 2.09 to 2.73), and 1.52 L/h (95% CI, 1.33 to 1.74) in carriers of the CYP2C9 genotypes *1/*1, *1/*3, and *3/*3, respectively.",Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12152005/),[l] / [h],2.38,202164,DB00917,Dinoprostone
,12152005,clearances,"The pharmacokinetics of racemic and of S-ibuprofen depended on the CYP2C9 isoleucine359leucine amino acid polymorphism: population mean S-ibuprofen clearances were 3.25 L/h (95% confidence interval [CI], 2.84 to 3.73), 2.38 L/h (95% CI, 2.09 to 2.73), and 1.52 L/h (95% CI, 1.33 to 1.74) in carriers of the CYP2C9 genotypes *1/*1, *1/*3, and *3/*3, respectively.",Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12152005/),[l] / [h],1.52,202165,DB00917,Dinoprostone
,23746590,peak meloxicam concentrations,"Mean peak meloxicam concentrations were 3.61±0 0.21 and 3.27±0.14 μg/mL with average elimination half-lives of 38.62±5.87 and 35.81±6.26 h for MEL-PRE and MEL-POST, respectively.",The effect of timing of oral meloxicam administration on physiological responses in calves after cautery dehorning with local anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23746590/),[μg] / [ml],3.61,202278,DB00917,Dinoprostone
,23746590,peak meloxicam concentrations,"Mean peak meloxicam concentrations were 3.61±0 0.21 and 3.27±0.14 μg/mL with average elimination half-lives of 38.62±5.87 and 35.81±6.26 h for MEL-PRE and MEL-POST, respectively.",The effect of timing of oral meloxicam administration on physiological responses in calves after cautery dehorning with local anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23746590/),[μg] / [ml],3.27,202279,DB00917,Dinoprostone
,23746590,elimination half-lives,"Mean peak meloxicam concentrations were 3.61±0 0.21 and 3.27±0.14 μg/mL with average elimination half-lives of 38.62±5.87 and 35.81±6.26 h for MEL-PRE and MEL-POST, respectively.",The effect of timing of oral meloxicam administration on physiological responses in calves after cautery dehorning with local anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23746590/),h,38.62,202280,DB00917,Dinoprostone
,23746590,elimination half-lives,"Mean peak meloxicam concentrations were 3.61±0 0.21 and 3.27±0.14 μg/mL with average elimination half-lives of 38.62±5.87 and 35.81±6.26 h for MEL-PRE and MEL-POST, respectively.",The effect of timing of oral meloxicam administration on physiological responses in calves after cautery dehorning with local anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23746590/),h,35.81,202281,DB00917,Dinoprostone
,16682968,IC(80),"IC(80) estimates obtained in vitro were similar for PGE(2) inhibition (130.8 +/- 11 and 131.9 +/- 19 10(-6) M, mean +/- s.d. for humans and rats, respectively), but slightly different for TXB(2) inhibition (103.9+/-15 and 151.4 +/- 40 10(-6) M, mean +/- s.d. for humans and rats, respectively, P < 0.05).",Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16682968/),10,130.8,212177,DB00917,Dinoprostone
,16682968,IC(80),"IC(80) estimates obtained in vitro were similar for PGE(2) inhibition (130.8 +/- 11 and 131.9 +/- 19 10(-6) M, mean +/- s.d. for humans and rats, respectively), but slightly different for TXB(2) inhibition (103.9+/-15 and 151.4 +/- 40 10(-6) M, mean +/- s.d. for humans and rats, respectively, P < 0.05).",Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16682968/),M,131.9,212178,DB00917,Dinoprostone
,16682968,IC(80),"IC(80) estimates obtained in vitro were similar for PGE(2) inhibition (130.8 +/- 11 and 131.9 +/- 19 10(-6) M, mean +/- s.d. for humans and rats, respectively), but slightly different for TXB(2) inhibition (103.9+/-15 and 151.4 +/- 40 10(-6) M, mean +/- s.d. for humans and rats, respectively, P < 0.05).",Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16682968/),10,103.9,212179,DB00917,Dinoprostone
,16682968,IC(80),"IC(80) estimates obtained in vitro were similar for PGE(2) inhibition (130.8 +/- 11 and 131.9 +/- 19 10(-6) M, mean +/- s.d. for humans and rats, respectively), but slightly different for TXB(2) inhibition (103.9+/-15 and 151.4 +/- 40 10(-6) M, mean +/- s.d. for humans and rats, respectively, P < 0.05).",Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16682968/),M,151.4,212180,DB00917,Dinoprostone
,16763096,half-life,"After DP-155 oral administration, indomethacin's half-life in the serum and the brain was 22 and 93 h, respectively, compared with 10 and 24 h following indomethacin oral administration.","A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763096/),h,22,218927,DB00917,Dinoprostone
,16763096,half-life,"After DP-155 oral administration, indomethacin's half-life in the serum and the brain was 22 and 93 h, respectively, compared with 10 and 24 h following indomethacin oral administration.","A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763096/),h,93,218928,DB00917,Dinoprostone
,16763096,half-life,"After DP-155 oral administration, indomethacin's half-life in the serum and the brain was 22 and 93 h, respectively, compared with 10 and 24 h following indomethacin oral administration.","A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763096/),h,10,218929,DB00917,Dinoprostone
,16763096,half-life,"After DP-155 oral administration, indomethacin's half-life in the serum and the brain was 22 and 93 h, respectively, compared with 10 and 24 h following indomethacin oral administration.","A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763096/),h,24,218930,DB00917,Dinoprostone
,9638074,tmax,"Tolfenamic acid pharmacokinetics were characterized by a relatively short tmax (0.94-2.04 h), a high estimated Vdarea (1.79-3.20 Lkg-1), an estimated t1/2 beta of 8.01-13.50 h and Cl beta of 0.142-0.175 Lkg-1h-1.",Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638074/),h,0.94-2.04,222966,DB00917,Dinoprostone
,9638074,Vdarea,"Tolfenamic acid pharmacokinetics were characterized by a relatively short tmax (0.94-2.04 h), a high estimated Vdarea (1.79-3.20 Lkg-1), an estimated t1/2 beta of 8.01-13.50 h and Cl beta of 0.142-0.175 Lkg-1h-1.",Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638074/),1/[lkg],1.79-3.20,222967,DB00917,Dinoprostone
,9638074,t1/2 beta,"Tolfenamic acid pharmacokinetics were characterized by a relatively short tmax (0.94-2.04 h), a high estimated Vdarea (1.79-3.20 Lkg-1), an estimated t1/2 beta of 8.01-13.50 h and Cl beta of 0.142-0.175 Lkg-1h-1.",Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638074/),h,8.01-13.50,222968,DB00917,Dinoprostone
,9638074,Cl beta,"Tolfenamic acid pharmacokinetics were characterized by a relatively short tmax (0.94-2.04 h), a high estimated Vdarea (1.79-3.20 Lkg-1), an estimated t1/2 beta of 8.01-13.50 h and Cl beta of 0.142-0.175 Lkg-1h-1.",Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638074/),1/[lkg],0.142-0.175,222969,DB00917,Dinoprostone
,12667184,Emax,"Both rac-KTP and the separate enantiomers produced marked inhibition of serum thromboxane B2 (TxB2) synthesis (ex vivo) and moderate inhibition of exudate prostaglandin E2 (PGE2) synthesis (in vivo); pharmacodynamic variables for S(+) KTP were Emax (%) = 94 and 100; IC50 (microg/mL) = 0.0033 and 0.0030; N = 0.45 and 0.58, respectively, where Emax is the maximal effect, IC50 the plasma drug concentration producing 50% of Emax and N the slope of log concentration/effect relationship.","Pharmacodynamics, chiral pharmacokinetics and PK-PD modelling of ketoprofen in the goat. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667184/),%,94,224987,DB00917,Dinoprostone
,12667184,Emax,"Both rac-KTP and the separate enantiomers produced marked inhibition of serum thromboxane B2 (TxB2) synthesis (ex vivo) and moderate inhibition of exudate prostaglandin E2 (PGE2) synthesis (in vivo); pharmacodynamic variables for S(+) KTP were Emax (%) = 94 and 100; IC50 (microg/mL) = 0.0033 and 0.0030; N = 0.45 and 0.58, respectively, where Emax is the maximal effect, IC50 the plasma drug concentration producing 50% of Emax and N the slope of log concentration/effect relationship.","Pharmacodynamics, chiral pharmacokinetics and PK-PD modelling of ketoprofen in the goat. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667184/),%,100,224988,DB00917,Dinoprostone
,12667184,IC50,"Both rac-KTP and the separate enantiomers produced marked inhibition of serum thromboxane B2 (TxB2) synthesis (ex vivo) and moderate inhibition of exudate prostaglandin E2 (PGE2) synthesis (in vivo); pharmacodynamic variables for S(+) KTP were Emax (%) = 94 and 100; IC50 (microg/mL) = 0.0033 and 0.0030; N = 0.45 and 0.58, respectively, where Emax is the maximal effect, IC50 the plasma drug concentration producing 50% of Emax and N the slope of log concentration/effect relationship.","Pharmacodynamics, chiral pharmacokinetics and PK-PD modelling of ketoprofen in the goat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667184/),[μg] / [ml],0.0033,224989,DB00917,Dinoprostone
,12667184,IC50,"Both rac-KTP and the separate enantiomers produced marked inhibition of serum thromboxane B2 (TxB2) synthesis (ex vivo) and moderate inhibition of exudate prostaglandin E2 (PGE2) synthesis (in vivo); pharmacodynamic variables for S(+) KTP were Emax (%) = 94 and 100; IC50 (microg/mL) = 0.0033 and 0.0030; N = 0.45 and 0.58, respectively, where Emax is the maximal effect, IC50 the plasma drug concentration producing 50% of Emax and N the slope of log concentration/effect relationship.","Pharmacodynamics, chiral pharmacokinetics and PK-PD modelling of ketoprofen in the goat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667184/),[μg] / [ml],0.00,224990,DB00917,Dinoprostone
,12667184,IC50 ratio,"The IC50 ratio, serum TxB2:exudate PGE2 was 1.10.","Pharmacodynamics, chiral pharmacokinetics and PK-PD modelling of ketoprofen in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667184/),,1.10,224991,DB00917,Dinoprostone
,7662598,natriuresis,"In the presence of angiotensin II, the furosemide-induced natriuresis decreased, that is, it was 174 +/- 14 versus 95 +/- 25 mumol/min (p < 0.05) and 187 +/- 17 versus 89 +/- 21 mumol/min (p < 0.05) for the 5 and the 10 mg/kg doses, respectively.",Furosemide dynamics in conscious rabbits: modulation by angiotensin II. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7662598/),[μM] / [min],174,225107,DB00917,Dinoprostone
,7662598,natriuresis,"In the presence of angiotensin II, the furosemide-induced natriuresis decreased, that is, it was 174 +/- 14 versus 95 +/- 25 mumol/min (p < 0.05) and 187 +/- 17 versus 89 +/- 21 mumol/min (p < 0.05) for the 5 and the 10 mg/kg doses, respectively.",Furosemide dynamics in conscious rabbits: modulation by angiotensin II. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7662598/),[μM] / [min],95,225108,DB00917,Dinoprostone
,7662598,natriuresis,"In the presence of angiotensin II, the furosemide-induced natriuresis decreased, that is, it was 174 +/- 14 versus 95 +/- 25 mumol/min (p < 0.05) and 187 +/- 17 versus 89 +/- 21 mumol/min (p < 0.05) for the 5 and the 10 mg/kg doses, respectively.",Furosemide dynamics in conscious rabbits: modulation by angiotensin II. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7662598/),[μM] / [min],187,225109,DB00917,Dinoprostone
,7662598,natriuresis,"In the presence of angiotensin II, the furosemide-induced natriuresis decreased, that is, it was 174 +/- 14 versus 95 +/- 25 mumol/min (p < 0.05) and 187 +/- 17 versus 89 +/- 21 mumol/min (p < 0.05) for the 5 and the 10 mg/kg doses, respectively.",Furosemide dynamics in conscious rabbits: modulation by angiotensin II. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7662598/),[μM] / [min],89,225110,DB00917,Dinoprostone
,29883889,dynamic,An assay dynamic range of 2 to 4000 ng/mL was achieved with a sample volume of 25 μL plasma on a Sciex API4000 instrument with simple protein precipitation.,"Bioanalysis of sulprostone, a prostaglandin E2 analogue and selective EP3 agonist, in monkey plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883889/),[ng] / [ml],2 to 4000,236144,DB00917,Dinoprostone
,3459864,Brain/plasma concentration ratio,"Brain/plasma concentration ratio of I was about 1.3, whereas that of II was about 0.05.","Biopharmaceutical studies on hydantoin derivatives. V. Pharmacokinetics and pharmacodynamics of 5,5-diphenylhydantoin and 1-benzenesulfonyl-5,5-diphenylhydantoin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459864/),,1.3,236528,DB00917,Dinoprostone
,3459864,Brain/plasma concentration ratio,"Brain/plasma concentration ratio of I was about 1.3, whereas that of II was about 0.05.","Biopharmaceutical studies on hydantoin derivatives. V. Pharmacokinetics and pharmacodynamics of 5,5-diphenylhydantoin and 1-benzenesulfonyl-5,5-diphenylhydantoin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459864/),,0.05,236529,DB00917,Dinoprostone
,3459864,Plasma protein binding,"Plasma protein binding of I having pKa value of 8.30 was about 88%, whereas that of II having pKa value of 4.89 was about 99%.","Biopharmaceutical studies on hydantoin derivatives. V. Pharmacokinetics and pharmacodynamics of 5,5-diphenylhydantoin and 1-benzenesulfonyl-5,5-diphenylhydantoin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459864/),%,88,236530,DB00917,Dinoprostone
,3459864,Plasma protein binding,"Plasma protein binding of I having pKa value of 8.30 was about 88%, whereas that of II having pKa value of 4.89 was about 99%.","Biopharmaceutical studies on hydantoin derivatives. V. Pharmacokinetics and pharmacodynamics of 5,5-diphenylhydantoin and 1-benzenesulfonyl-5,5-diphenylhydantoin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459864/),%,99,236531,DB00917,Dinoprostone
,19628498,peak vitreous concentration,"Ketorolac and diclofenac achieved a peak vitreous concentration of 234 and 73 microg/ml, respectively.",Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628498/),[μg] / [ml],234,245012,DB00917,Dinoprostone
,19628498,peak vitreous concentration,"Ketorolac and diclofenac achieved a peak vitreous concentration of 234 and 73 microg/ml, respectively.",Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628498/),[μg] / [ml],73,245013,DB00917,Dinoprostone
,19628498,peak concentration,The peak concentration of each drug in the retina/choroid was 201 microg/g for ketorolac and 4.1 microg/g for diclofenac.,Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628498/),[μg] / [g],201,245014,DB00917,Dinoprostone
,19628498,peak concentration,The peak concentration of each drug in the retina/choroid was 201 microg/g for ketorolac and 4.1 microg/g for diclofenac.,Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628498/),[μg] / [g],4.1,245015,DB00917,Dinoprostone
,3176518,Systemic bioavailability,Systemic bioavailability of unchanged active acid was only 7.3%.,Pre-systemic metabolism of viprostol in the monkey following oral and topical administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176518/),%,7.3,249167,DB00917,Dinoprostone
,3176518,transdermal absorption,"3. After topical dosing, transdermal absorption of total radioactivity by 48 h averaged only 5% of dose.",Pre-systemic metabolism of viprostol in the monkey following oral and topical administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176518/),%,5,249168,DB00917,Dinoprostone
,3176518,Absolute bioavailability,Absolute bioavailability of II averaged 3.8% of dose.,Pre-systemic metabolism of viprostol in the monkey following oral and topical administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176518/),%,3.8,249169,DB00917,Dinoprostone
,21781136,internal volume,"Four cylindrical silicon tissue cages (TC, internal volume: 6.7 ± 0.11 cm(3)) were inserted subcutaneously in 29 young healthy cats.",Development and validation of a tissue cage model of acute inflammation in the cat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781136/),cm(3),6.7,262625,DB00917,Dinoprostone
,18397691,Maximal inhibition,"Maximal inhibition after a single dose and at steady state were as follows: 94% and 93% (COX-1), and 79% and 85% (COX-2).",Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397691/),%,94,265467,DB00917,Dinoprostone
,18397691,Maximal inhibition,"Maximal inhibition after a single dose and at steady state were as follows: 94% and 93% (COX-1), and 79% and 85% (COX-2).",Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397691/),%,93,265468,DB00917,Dinoprostone
,18397691,Maximal inhibition,"Maximal inhibition after a single dose and at steady state were as follows: 94% and 93% (COX-1), and 79% and 85% (COX-2).",Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397691/),%,79,265469,DB00917,Dinoprostone
,18397691,Maximal inhibition,"Maximal inhibition after a single dose and at steady state were as follows: 94% and 93% (COX-1), and 79% and 85% (COX-2).",Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397691/),%,85,265470,DB00917,Dinoprostone
,18397691,IC50,"For both isoenzymes, COX inhibition correlated with naproxen plasma levels (ex vivo IC50 values of 35.48 micromol/l (COX-1) and 64.62 micromol/l (COX-2)).",Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397691/),[μM] / [l],35.48,265471,DB00917,Dinoprostone
,18397691,IC50,"For both isoenzymes, COX inhibition correlated with naproxen plasma levels (ex vivo IC50 values of 35.48 micromol/l (COX-1) and 64.62 micromol/l (COX-2)).",Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397691/),[μM] / [l],64.62,265472,DB00917,Dinoprostone
,21347567,IC(50),"The IC(50) values (95% CI) of naproxen for analgesia (27 (0-130) μM), antipyretics (40 (30-65) μM) and inhibition of PGE(2) (13 (6-45) μM) were in similar range, whereas inhibition of TXB(2) (5 (4-8) μM) was observed at lower concentrations.","Pharmacokinetic-pharmacodynamic modeling of the inhibitory effects of naproxen on the time-courses of inflammatory pain, fever, and the ex vivo synthesis of TXB2 and PGE2 in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21347567/),μM,27,266033,DB00917,Dinoprostone
,21347567,IC(50),"The IC(50) values (95% CI) of naproxen for analgesia (27 (0-130) μM), antipyretics (40 (30-65) μM) and inhibition of PGE(2) (13 (6-45) μM) were in similar range, whereas inhibition of TXB(2) (5 (4-8) μM) was observed at lower concentrations.","Pharmacokinetic-pharmacodynamic modeling of the inhibitory effects of naproxen on the time-courses of inflammatory pain, fever, and the ex vivo synthesis of TXB2 and PGE2 in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21347567/),μM,40,266034,DB00917,Dinoprostone
,21347567,IC(50),"The IC(50) values (95% CI) of naproxen for analgesia (27 (0-130) μM), antipyretics (40 (30-65) μM) and inhibition of PGE(2) (13 (6-45) μM) were in similar range, whereas inhibition of TXB(2) (5 (4-8) μM) was observed at lower concentrations.","Pharmacokinetic-pharmacodynamic modeling of the inhibitory effects of naproxen on the time-courses of inflammatory pain, fever, and the ex vivo synthesis of TXB2 and PGE2 in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21347567/),μM,13,266035,DB00917,Dinoprostone
,21347567,IC(50),"The IC(50) values (95% CI) of naproxen for analgesia (27 (0-130) μM), antipyretics (40 (30-65) μM) and inhibition of PGE(2) (13 (6-45) μM) were in similar range, whereas inhibition of TXB(2) (5 (4-8) μM) was observed at lower concentrations.","Pharmacokinetic-pharmacodynamic modeling of the inhibitory effects of naproxen on the time-courses of inflammatory pain, fever, and the ex vivo synthesis of TXB2 and PGE2 in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21347567/),μM,5,266036,DB00917,Dinoprostone
